US20200115757A9 - Test kits and methods for their use to detect genetic markers for urothelial carcinoma of the bladder and treatment thereof - Google Patents
Test kits and methods for their use to detect genetic markers for urothelial carcinoma of the bladder and treatment thereof Download PDFInfo
- Publication number
- US20200115757A9 US20200115757A9 US15/798,922 US201715798922A US2020115757A9 US 20200115757 A9 US20200115757 A9 US 20200115757A9 US 201715798922 A US201715798922 A US 201715798922A US 2020115757 A9 US2020115757 A9 US 2020115757A9
- Authority
- US
- United States
- Prior art keywords
- protein
- transcript variant
- transcript
- mrna
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010044412 transitional cell carcinoma Diseases 0.000 title claims abstract description 42
- 230000002068 genetic effect Effects 0.000 title claims abstract 7
- 238000011282 treatment Methods 0.000 title description 11
- 238000003149 assay kit Methods 0.000 title description 3
- 238000010998 test method Methods 0.000 title 1
- 208000023747 urothelial carcinoma Diseases 0.000 title 1
- 230000014509 gene expression Effects 0.000 claims abstract description 60
- 238000001514 detection method Methods 0.000 claims abstract description 45
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 98
- 239000000523 sample Substances 0.000 claims description 98
- 108090000623 proteins and genes Proteins 0.000 claims description 79
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 72
- 101000589859 Homo sapiens Prostaglandin reductase 1 Proteins 0.000 claims description 65
- 102100032258 Prostaglandin reductase 1 Human genes 0.000 claims description 64
- 238000012360 testing method Methods 0.000 claims description 57
- 239000002299 complementary DNA Substances 0.000 claims description 55
- 108020004999 messenger RNA Proteins 0.000 claims description 51
- 230000002441 reversible effect Effects 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 201000011510 cancer Diseases 0.000 claims description 35
- 108091034117 Oligonucleotide Proteins 0.000 claims description 34
- 101000840566 Homo sapiens Insulin-like growth factor-binding protein 5 Proteins 0.000 claims description 33
- 102100029225 Insulin-like growth factor-binding protein 5 Human genes 0.000 claims description 33
- 108020004414 DNA Proteins 0.000 claims description 31
- 108010021685 homeobox protein HOXA13 Proteins 0.000 claims description 29
- 101000990990 Homo sapiens Midkine Proteins 0.000 claims description 28
- 239000007850 fluorescent dye Substances 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 102100037152 BAG family molecular chaperone regulator 1 Human genes 0.000 claims description 17
- 101000740062 Homo sapiens BAG family molecular chaperone regulator 1 Proteins 0.000 claims description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- WVAKRQOMAINQPU-UHFFFAOYSA-N 2-[4-[2-[5-(2,2-dimethylbutyl)-1h-imidazol-2-yl]ethyl]phenyl]pyridine Chemical compound N1C(CC(C)(C)CC)=CN=C1CCC1=CC=C(C=2N=CC=CC=2)C=C1 WVAKRQOMAINQPU-UHFFFAOYSA-N 0.000 claims description 15
- 102100030335 Midkine Human genes 0.000 claims description 13
- 102100030307 Homeobox protein Hox-A13 Human genes 0.000 claims description 11
- 101000730866 Homo sapiens PGAP2-interacting protein Proteins 0.000 claims description 10
- 102100032940 PGAP2-interacting protein Human genes 0.000 claims description 10
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 2
- 102100033587 DNA topoisomerase 2-alpha Human genes 0.000 claims 16
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims 13
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims 6
- 102100034870 Kallikrein-8 Human genes 0.000 claims 5
- 102100040023 Adhesion G-protein coupled receptor G6 Human genes 0.000 claims 4
- 101710096338 Adhesion G-protein coupled receptor G6 Proteins 0.000 claims 4
- 102100022480 Cadherin-20 Human genes 0.000 claims 4
- 102100024485 Cell division cycle-associated protein 7 Human genes 0.000 claims 4
- 102100029362 Cone-rod homeobox protein Human genes 0.000 claims 4
- 102100040455 Cyclic nucleotide-binding domain-containing protein 2 Human genes 0.000 claims 4
- 102100021603 DNA excision repair protein ERCC-6-like 2 Human genes 0.000 claims 4
- 102100029984 Dynein axonemal light chain 1 Human genes 0.000 claims 4
- 102100032049 E3 ubiquitin-protein ligase LRSAM1 Human genes 0.000 claims 4
- 102100030456 Follistatin-related protein 4 Human genes 0.000 claims 4
- 102100037042 Forkhead box protein E1 Human genes 0.000 claims 4
- 102100033495 Glycine dehydrogenase (decarboxylating), mitochondrial Human genes 0.000 claims 4
- 102100029481 Glycogen phosphorylase, liver form Human genes 0.000 claims 4
- 102100034338 Glycosyl-phosphatidylinositol-anchored molecule-like protein Human genes 0.000 claims 4
- 102100034155 Guanine nucleotide-binding protein G(i) subunit alpha-1 Human genes 0.000 claims 4
- 102100035944 HERV-H LTR-associating protein 3 Human genes 0.000 claims 4
- 102100036284 Hepcidin Human genes 0.000 claims 4
- 102100023830 Homeobox protein EMX2 Human genes 0.000 claims 4
- 102100034858 Homeobox protein Hox-D8 Human genes 0.000 claims 4
- 101000899459 Homo sapiens Cadherin-20 Proteins 0.000 claims 4
- 101000980893 Homo sapiens Cell division cycle-associated protein 7 Proteins 0.000 claims 4
- 101000919370 Homo sapiens Cone-rod homeobox protein Proteins 0.000 claims 4
- 101000749817 Homo sapiens Cyclic nucleotide-binding domain-containing protein 2 Proteins 0.000 claims 4
- 101000898683 Homo sapiens DNA excision repair protein ERCC-6-like 2 Proteins 0.000 claims 4
- 101000863725 Homo sapiens Dynein axonemal light chain 1 Proteins 0.000 claims 4
- 101001065747 Homo sapiens E3 ubiquitin-protein ligase LRSAM1 Proteins 0.000 claims 4
- 101001062597 Homo sapiens Follistatin-related protein 4 Proteins 0.000 claims 4
- 101001029304 Homo sapiens Forkhead box protein E1 Proteins 0.000 claims 4
- 101000998096 Homo sapiens Glycine dehydrogenase (decarboxylating), mitochondrial Proteins 0.000 claims 4
- 101000997053 Homo sapiens Glycosyl-phosphatidylinositol-anchored molecule-like protein Proteins 0.000 claims 4
- 101001070526 Homo sapiens Guanine nucleotide-binding protein G(i) subunit alpha-1 Proteins 0.000 claims 4
- 101001021492 Homo sapiens HERV-H LTR-associating protein 3 Proteins 0.000 claims 4
- 101001021253 Homo sapiens Hepcidin Proteins 0.000 claims 4
- 101001048970 Homo sapiens Homeobox protein EMX2 Proteins 0.000 claims 4
- 101001019776 Homo sapiens Homeobox protein Hox-D8 Proteins 0.000 claims 4
- 101001091371 Homo sapiens Kallikrein-8 Proteins 0.000 claims 4
- 101000619927 Homo sapiens LIM/homeobox protein Lhx9 Proteins 0.000 claims 4
- 101000893530 Homo sapiens Leucine-rich repeat transmembrane protein FLRT3 Proteins 0.000 claims 4
- 101000611345 Homo sapiens Olfactory receptor 1D5 Proteins 0.000 claims 4
- 101000736367 Homo sapiens PH and SEC7 domain-containing protein 3 Proteins 0.000 claims 4
- 101001114076 Homo sapiens Paladin Proteins 0.000 claims 4
- 101000596041 Homo sapiens Plastin-1 Proteins 0.000 claims 4
- 101001090935 Homo sapiens Regulator of nonsense transcripts 3A Proteins 0.000 claims 4
- 101000880385 Homo sapiens STING ER exit protein Proteins 0.000 claims 4
- 101000596334 Homo sapiens TSC22 domain family protein 1 Proteins 0.000 claims 4
- 101000658644 Homo sapiens Tetratricopeptide repeat protein 21A Proteins 0.000 claims 4
- 101000664577 Homo sapiens Tripartite motif-containing protein 10 Proteins 0.000 claims 4
- 101000702706 Homo sapiens Uncharacterized protein encoded by SND1-IT1 Proteins 0.000 claims 4
- 101000785632 Homo sapiens Zinc finger FYVE domain-containing protein 21 Proteins 0.000 claims 4
- 102100022966 Inactive glycosyltransferase 25 family member 3 Human genes 0.000 claims 4
- 102100022141 LIM/homeobox protein Lhx9 Human genes 0.000 claims 4
- 102100040900 Leucine-rich repeat transmembrane protein FLRT3 Human genes 0.000 claims 4
- 108010058682 Mitochondrial Proteins Proteins 0.000 claims 4
- 102000006404 Mitochondrial Proteins Human genes 0.000 claims 4
- 101000893529 Mus musculus Leucine-rich repeat transmembrane protein FLRT3 Proteins 0.000 claims 4
- 102100040774 Olfactory receptor 1D5 Human genes 0.000 claims 4
- 102100036231 PH and SEC7 domain-containing protein 3 Human genes 0.000 claims 4
- 102100036877 PHD finger protein 23 Human genes 0.000 claims 4
- 101710106173 PHD finger protein 23 Proteins 0.000 claims 4
- 102100023224 Paladin Human genes 0.000 claims 4
- 102100035181 Plastin-1 Human genes 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 4
- 102100026352 RING finger protein 44 Human genes 0.000 claims 4
- 101710119864 RING finger protein 44 Proteins 0.000 claims 4
- 102100021314 Rab11 family-interacting protein 2 Human genes 0.000 claims 4
- 102100035026 Regulator of nonsense transcripts 3A Human genes 0.000 claims 4
- 102100037658 STING ER exit protein Human genes 0.000 claims 4
- 108010027912 Sulfite Oxidase Proteins 0.000 claims 4
- 102000043440 Sulfite oxidase Human genes 0.000 claims 4
- 102100035051 TSC22 domain family protein 1 Human genes 0.000 claims 4
- 102100034913 Tetratricopeptide repeat protein 21A Human genes 0.000 claims 4
- 102100038801 Tripartite motif-containing protein 10 Human genes 0.000 claims 4
- 102100030915 Uncharacterized protein encoded by SND1-IT1 Human genes 0.000 claims 4
- 102100026462 Zinc finger FYVE domain-containing protein 21 Human genes 0.000 claims 4
- 102100034825 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Human genes 0.000 claims 4
- 101710143997 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Proteins 0.000 claims 4
- -1 (CAPN13) Proteins 0.000 claims 3
- 108091006027 G proteins Proteins 0.000 claims 3
- 102100035924 Gamma-aminobutyric acid type B receptor subunit 2 Human genes 0.000 claims 3
- 101710086265 Gamma-aminobutyric acid type B receptor subunit 2 Proteins 0.000 claims 3
- 101000801505 Homo sapiens DNA topoisomerase 2-alpha Proteins 0.000 claims 3
- 101000700616 Homo sapiens Glycogen phosphorylase, liver form Proteins 0.000 claims 3
- 101000808590 Homo sapiens Probable ubiquitin carboxyl-terminal hydrolase FAF-Y Proteins 0.000 claims 3
- 101000804728 Homo sapiens Protein Wnt-2b Proteins 0.000 claims 3
- 102100028614 Palmitoyltransferase ZDHHC2 Human genes 0.000 claims 3
- 101710098464 Palmitoyltransferase ZDHHC2 Proteins 0.000 claims 3
- 102100038600 Probable ubiquitin carboxyl-terminal hydrolase FAF-Y Human genes 0.000 claims 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 3
- 102100035289 Protein Wnt-2b Human genes 0.000 claims 3
- 102100029147 Retrotransposon Gag-like protein 6 Human genes 0.000 claims 3
- 101710154066 Retrotransposon Gag-like protein 6 Proteins 0.000 claims 3
- 102100035800 Zinc finger protein 626 Human genes 0.000 claims 3
- 101710144047 Zinc finger protein 626 Proteins 0.000 claims 3
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 2
- 102100038074 5'-AMP-activated protein kinase subunit beta-1 Human genes 0.000 claims 2
- 102100027783 ADP-ribose glycohydrolase OARD1 Human genes 0.000 claims 2
- 102100036610 AN1-type zinc finger protein 5 Human genes 0.000 claims 2
- 102100032746 Actin-histidine N-methyltransferase Human genes 0.000 claims 2
- 102000007476 Activating Transcription Factor 3 Human genes 0.000 claims 2
- 108010085371 Activating Transcription Factor 3 Proteins 0.000 claims 2
- 102100031795 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Human genes 0.000 claims 2
- 102100024085 Alpha-aminoadipic semialdehyde dehydrogenase Human genes 0.000 claims 2
- 102100031619 Alpha-tocopherol transfer protein-like Human genes 0.000 claims 2
- 102100032187 Androgen receptor Human genes 0.000 claims 2
- 102100035553 Autism susceptibility gene 2 protein Human genes 0.000 claims 2
- 101710180107 Autism susceptibility gene 2 protein Proteins 0.000 claims 2
- 102100026434 BCAS3 microtubule associated cell migration factor Human genes 0.000 claims 2
- 102100040534 BTB/POZ domain-containing protein KCTD3 Human genes 0.000 claims 2
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 claims 2
- 101710120270 Bone morphogenetic protein receptor type-1A Proteins 0.000 claims 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 2
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 2
- 102100033787 CMP-sialic acid transporter Human genes 0.000 claims 2
- 102100037720 Calcium load-activated calcium channel Human genes 0.000 claims 2
- 102100036293 Calcium-binding mitochondrial carrier protein SCaMC-3 Human genes 0.000 claims 2
- 101710189676 Calcium-binding mitochondrial carrier protein SCaMC-3 Proteins 0.000 claims 2
- 102100035882 Catalase Human genes 0.000 claims 2
- 108010053835 Catalase Proteins 0.000 claims 2
- 102100035654 Cathepsin S Human genes 0.000 claims 2
- 102100037622 Centromere protein T Human genes 0.000 claims 2
- 102100031203 Centrosomal protein 43 Human genes 0.000 claims 2
- 101710182224 Centrosomal protein 43 Proteins 0.000 claims 2
- 102100034229 Citramalyl-CoA lyase, mitochondrial Human genes 0.000 claims 2
- 101710083706 Citramalyl-CoA lyase, mitochondrial Proteins 0.000 claims 2
- 108010067499 Clk dual-specificity kinases Proteins 0.000 claims 2
- 102100021981 Coiled-coil domain-containing protein 28A Human genes 0.000 claims 2
- 102100037078 Complement component 1 Q subcomponent-binding protein, mitochondrial Human genes 0.000 claims 2
- 108090000404 Cyclin G1 Proteins 0.000 claims 2
- 102000004012 Cyclin G1 Human genes 0.000 claims 2
- 102100028180 Cysteine-rich and transmembrane domain-containing protein 1 Human genes 0.000 claims 2
- 102100029861 Cytochrome b-c1 complex subunit 8 Human genes 0.000 claims 2
- 102100039077 Cytosolic 10-formyltetrahydrofolate dehydrogenase Human genes 0.000 claims 2
- 102100026139 DNA damage-inducible transcript 4 protein Human genes 0.000 claims 2
- 102100039694 Death-associated protein 1 Human genes 0.000 claims 2
- 102100029588 Deoxycytidine kinase Human genes 0.000 claims 2
- 102100035046 Dimethylaniline monooxygenase [N-oxide-forming] 4 Human genes 0.000 claims 2
- 102100037983 Disks large-associated protein 4 Human genes 0.000 claims 2
- 102100035425 DnaJ homolog subfamily B member 6 Human genes 0.000 claims 2
- 102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 claims 2
- 102100027088 Dual specificity protein phosphatase 5 Human genes 0.000 claims 2
- 102100032234 Dynein axonemal assembly factor 6 Human genes 0.000 claims 2
- 102100026464 E3 ubiquitin-protein ligase RNF38 Human genes 0.000 claims 2
- 101710109256 E3 ubiquitin-protein ligase RNF38 Proteins 0.000 claims 2
- 102100039639 E3 ubiquitin-protein ligase pellino homolog 1 Human genes 0.000 claims 2
- 102100034582 E3 ubiquitin/ISG15 ligase TRIM25 Human genes 0.000 claims 2
- 102100029652 EH domain-binding protein 1 Human genes 0.000 claims 2
- 101710165824 EH domain-binding protein 1 Proteins 0.000 claims 2
- 102100032037 EH domain-containing protein 4 Human genes 0.000 claims 2
- 102100027304 Eukaryotic translation initiation factor 4E Human genes 0.000 claims 2
- 101710091918 Eukaryotic translation initiation factor 4E Proteins 0.000 claims 2
- 102100026980 Exocyst complex component 5 Human genes 0.000 claims 2
- 102100040641 F-box only protein 34 Human genes 0.000 claims 2
- 102100040351 FK506-binding protein 15 Human genes 0.000 claims 2
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 claims 2
- 102100040988 Formin-binding protein 4 Human genes 0.000 claims 2
- 101710130475 Formin-binding protein 4 Proteins 0.000 claims 2
- 102100025413 Formyltetrahydrofolate synthetase Human genes 0.000 claims 2
- 102000030782 GTP binding Human genes 0.000 claims 2
- 108091000058 GTP-Binding Proteins 0.000 claims 2
- 102100039558 Galectin-3 Human genes 0.000 claims 2
- 102100039956 Geminin Human genes 0.000 claims 2
- 102100036621 Glucosylceramide transporter ABCA12 Human genes 0.000 claims 2
- 102100029846 Glutaminyl-peptide cyclotransferase Human genes 0.000 claims 2
- 208000032002 Glycogen storage disease due to liver glycogen phosphorylase deficiency Diseases 0.000 claims 2
- 206010053240 Glycogen storage disease type VI Diseases 0.000 claims 2
- 102100023849 Glycophorin-C Human genes 0.000 claims 2
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 claims 2
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 claims 2
- 102100031153 Growth arrest and DNA damage-inducible protein GADD45 beta Human genes 0.000 claims 2
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims 2
- 102100034339 Guanine nucleotide-binding protein G(olf) subunit alpha Human genes 0.000 claims 2
- 102100027703 Heterogeneous nuclear ribonucleoprotein H2 Human genes 0.000 claims 2
- 101710203726 Heterogeneous nuclear ribonucleoprotein H2 Proteins 0.000 claims 2
- 108010026764 High-Temperature Requirement A Serine Peptidase 2 Proteins 0.000 claims 2
- 102000018980 High-Temperature Requirement A Serine Peptidase 2 Human genes 0.000 claims 2
- 102100029234 Histone-lysine N-methyltransferase NSD2 Human genes 0.000 claims 2
- 102100035009 Holocytochrome c-type synthase Human genes 0.000 claims 2
- 102100034862 Homeobox protein Hox-B2 Human genes 0.000 claims 2
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 claims 2
- 101000742701 Homo sapiens 5'-AMP-activated protein kinase subunit beta-1 Proteins 0.000 claims 2
- 101001008861 Homo sapiens ADP-ribose glycohydrolase OARD1 Proteins 0.000 claims 2
- 101000782077 Homo sapiens AN1-type zinc finger protein 5 Proteins 0.000 claims 2
- 101000654703 Homo sapiens Actin-histidine N-methyltransferase Proteins 0.000 claims 2
- 101000775437 Homo sapiens All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 claims 2
- 101000690235 Homo sapiens Alpha-aminoadipic semialdehyde dehydrogenase Proteins 0.000 claims 2
- 101000795757 Homo sapiens Alpha-tocopherol transfer protein-like Proteins 0.000 claims 2
- 101000766273 Homo sapiens BCAS3 microtubule associated cell migration factor Proteins 0.000 claims 2
- 101000613894 Homo sapiens BTB/POZ domain-containing protein KCTD3 Proteins 0.000 claims 2
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 2
- 101000663041 Homo sapiens Calcium load-activated calcium channel Proteins 0.000 claims 2
- 101000880504 Homo sapiens Centromere protein T Proteins 0.000 claims 2
- 101000896971 Homo sapiens Coiled-coil domain-containing protein 28A Proteins 0.000 claims 2
- 101000916674 Homo sapiens Cysteine-rich and transmembrane domain-containing protein 1 Proteins 0.000 claims 2
- 101000585358 Homo sapiens Cytochrome b-c1 complex subunit 8 Proteins 0.000 claims 2
- 101000959030 Homo sapiens Cytosolic 10-formyltetrahydrofolate dehydrogenase Proteins 0.000 claims 2
- 101000912753 Homo sapiens DNA damage-inducible transcript 4 protein Proteins 0.000 claims 2
- 101000951335 Homo sapiens Disks large-associated protein 4 Proteins 0.000 claims 2
- 101000804112 Homo sapiens DnaJ homolog subfamily B member 6 Proteins 0.000 claims 2
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 claims 2
- 101000869177 Homo sapiens Dynein axonemal assembly factor 6 Proteins 0.000 claims 2
- 101000606708 Homo sapiens E3 ubiquitin-protein ligase pellino homolog 1 Proteins 0.000 claims 2
- 101000848655 Homo sapiens E3 ubiquitin/ISG15 ligase TRIM25 Proteins 0.000 claims 2
- 101000921218 Homo sapiens EH domain-containing protein 4 Proteins 0.000 claims 2
- 101000911703 Homo sapiens Exocyst complex component 5 Proteins 0.000 claims 2
- 101000892349 Homo sapiens F-box only protein 34 Proteins 0.000 claims 2
- 101000891018 Homo sapiens FK506-binding protein 15 Proteins 0.000 claims 2
- 101000886596 Homo sapiens Geminin Proteins 0.000 claims 2
- 101000929652 Homo sapiens Glucosylceramide transporter ABCA12 Proteins 0.000 claims 2
- 101000905336 Homo sapiens Glycophorin-C Proteins 0.000 claims 2
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 claims 2
- 101001066164 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 beta Proteins 0.000 claims 2
- 101000997083 Homo sapiens Guanine nucleotide-binding protein G(olf) subunit alpha Proteins 0.000 claims 2
- 101000946589 Homo sapiens Holocytochrome c-type synthase Proteins 0.000 claims 2
- 101001083162 Homo sapiens Homeobox protein Hox-A13 Proteins 0.000 claims 2
- 101001019752 Homo sapiens Homeobox protein Hox-B2 Proteins 0.000 claims 2
- 101001035135 Homo sapiens Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 2 protein Proteins 0.000 claims 2
- 101001042781 Homo sapiens Hydroxysteroid dehydrogenase-like protein 2 Proteins 0.000 claims 2
- 101001011412 Homo sapiens IQ calmodulin-binding motif-containing protein 1 Proteins 0.000 claims 2
- 101001077840 Homo sapiens Lipid-phosphate phosphatase Proteins 0.000 claims 2
- 101001064427 Homo sapiens Liprin-beta-2 Proteins 0.000 claims 2
- 101001088893 Homo sapiens Lysine-specific demethylase 4C Proteins 0.000 claims 2
- 101001098256 Homo sapiens Lysophospholipase Proteins 0.000 claims 2
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 claims 2
- 101000588145 Homo sapiens Microtubule-associated tumor suppressor 1 Proteins 0.000 claims 2
- 101000574253 Homo sapiens Mitochondrial fission factor Proteins 0.000 claims 2
- 101000585663 Homo sapiens Myocilin Proteins 0.000 claims 2
- 101000886220 Homo sapiens N-acetylgalactosaminyltransferase 7 Proteins 0.000 claims 2
- 101001023513 Homo sapiens NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial Proteins 0.000 claims 2
- 101000998623 Homo sapiens NADH-cytochrome b5 reductase 3 Proteins 0.000 claims 2
- 101000624947 Homo sapiens Nesprin-1 Proteins 0.000 claims 2
- 101000962058 Homo sapiens Neurobeachin-like protein 1 Proteins 0.000 claims 2
- 101001038660 Homo sapiens Nucleolar protein 6 Proteins 0.000 claims 2
- 101000721386 Homo sapiens OTU domain-containing protein 5 Proteins 0.000 claims 2
- 101001129621 Homo sapiens PH domain leucine-rich repeat-containing protein phosphatase 1 Proteins 0.000 claims 2
- 101000601664 Homo sapiens Paired box protein Pax-8 Proteins 0.000 claims 2
- 101000610202 Homo sapiens Poly(A) polymerase beta Proteins 0.000 claims 2
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 claims 2
- 101001069595 Homo sapiens Probable G-protein coupled receptor 83 Proteins 0.000 claims 2
- 101001098989 Homo sapiens Propionyl-CoA carboxylase alpha chain, mitochondrial Proteins 0.000 claims 2
- 101000988156 Homo sapiens Prostate and breast cancer overexpressed gene 1 protein Proteins 0.000 claims 2
- 101000574242 Homo sapiens RING-type E3 ubiquitin-protein ligase PPIL2 Proteins 0.000 claims 2
- 101001048702 Homo sapiens RNA polymerase II elongation factor ELL2 Proteins 0.000 claims 2
- 101000683507 Homo sapiens RRP12-like protein Proteins 0.000 claims 2
- 101000581112 Homo sapiens Rho-related GTP-binding protein RhoB Proteins 0.000 claims 2
- 101001010890 Homo sapiens S-formylglutathione hydrolase Proteins 0.000 claims 2
- 101000837007 Homo sapiens SH3 domain-binding glutamic acid-rich-like protein 2 Proteins 0.000 claims 2
- 101000576901 Homo sapiens Serine/threonine-protein kinase MRCK alpha Proteins 0.000 claims 2
- 101000588553 Homo sapiens Serine/threonine-protein kinase Nek9 Proteins 0.000 claims 2
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 claims 2
- 101000802053 Homo sapiens THUMP domain-containing protein 1 Proteins 0.000 claims 2
- 101000596277 Homo sapiens TSC22 domain family protein 3 Proteins 0.000 claims 2
- 101000653435 Homo sapiens Tectonic-3 Proteins 0.000 claims 2
- 101000830710 Homo sapiens Torsin-4A Proteins 0.000 claims 2
- 101000680123 Homo sapiens Transmembrane and coiled-coil domain-containing protein 4 Proteins 0.000 claims 2
- 101000801092 Homo sapiens Transmembrane protein 203 Proteins 0.000 claims 2
- 101000763003 Homo sapiens Two pore channel protein 1 Proteins 0.000 claims 2
- 101000888372 Homo sapiens UPF0686 protein C11orf1 Proteins 0.000 claims 2
- 101000771607 Homo sapiens WD repeat-containing protein 61 Proteins 0.000 claims 2
- 101000723887 Homo sapiens Zinc finger matrin-type protein 1 Proteins 0.000 claims 2
- 101000788892 Homo sapiens Zinc finger protein 280C Proteins 0.000 claims 2
- 101000824944 Homo sapiens snRNA-activating protein complex subunit 5 Proteins 0.000 claims 2
- 101000804630 Homo sapiens von Willebrand factor A domain-containing protein 5B2 Proteins 0.000 claims 2
- 102100039926 Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 2 protein Human genes 0.000 claims 2
- 102100021656 Hydroxysteroid dehydrogenase-like protein 2 Human genes 0.000 claims 2
- 102100029842 IQ calmodulin-binding motif-containing protein 1 Human genes 0.000 claims 2
- 101710187845 Inactive glycosyltransferase 25 family member 3 Proteins 0.000 claims 2
- 102100020880 Kit ligand Human genes 0.000 claims 2
- 102100031035 Leucine-rich repeat-containing G-protein coupled receptor 4 Human genes 0.000 claims 2
- 102100025357 Lipid-phosphate phosphatase Human genes 0.000 claims 2
- 102100031981 Liprin-beta-2 Human genes 0.000 claims 2
- 102100033230 Lysine-specific demethylase 4C Human genes 0.000 claims 2
- 102100037611 Lysophospholipase Human genes 0.000 claims 2
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 claims 2
- 102100026108 Microfibrillar-associated protein 3-like Human genes 0.000 claims 2
- 101710174562 Microfibrillar-associated protein 3-like Proteins 0.000 claims 2
- 102100021794 Microtubule-associated protein 4 Human genes 0.000 claims 2
- 101710093519 Microtubule-associated protein 4 Proteins 0.000 claims 2
- 102100031550 Microtubule-associated tumor suppressor 1 Human genes 0.000 claims 2
- 108010092801 Midkine Proteins 0.000 claims 2
- 102100025782 Mitochondrial fission factor Human genes 0.000 claims 2
- 102100029839 Myocilin Human genes 0.000 claims 2
- 102100039679 N-acetylgalactosaminyltransferase 7 Human genes 0.000 claims 2
- 102100035383 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial Human genes 0.000 claims 2
- 102100033153 NADH-cytochrome b5 reductase 3 Human genes 0.000 claims 2
- 108090000424 NADPH Oxidase 1 Proteins 0.000 claims 2
- 102100021873 NADPH oxidase 1 Human genes 0.000 claims 2
- 102100034431 Nebulette Human genes 0.000 claims 2
- 101710113660 Nebulette Proteins 0.000 claims 2
- 102100023306 Nesprin-1 Human genes 0.000 claims 2
- 102100039231 Neurobeachin-like protein 1 Human genes 0.000 claims 2
- 102100035402 Nuclear RNA export factor 1 Human genes 0.000 claims 2
- 101710139195 Nuclear RNA export factor 1 Proteins 0.000 claims 2
- 102100040759 Nucleolar protein 6 Human genes 0.000 claims 2
- 102100022396 Nucleosome assembly protein 1-like 4 Human genes 0.000 claims 2
- 101710192965 Nucleosome assembly protein 1-like 4 Proteins 0.000 claims 2
- 102100025194 OTU domain-containing protein 5 Human genes 0.000 claims 2
- 102100031152 PH domain leucine-rich repeat-containing protein phosphatase 1 Human genes 0.000 claims 2
- 102100037502 Paired box protein Pax-8 Human genes 0.000 claims 2
- 102100025731 Phosphatidate phosphatase LPIN1 Human genes 0.000 claims 2
- 108050005456 Phosphatidate phosphatase LPIN1 Proteins 0.000 claims 2
- 102100034078 Phosphofurin acidic cluster sorting protein 1 Human genes 0.000 claims 2
- 101710135643 Phosphofurin acidic cluster sorting protein 1 Proteins 0.000 claims 2
- 102100040207 Poly(A) polymerase beta Human genes 0.000 claims 2
- 102100026531 Prelamin-A/C Human genes 0.000 claims 2
- 102100033865 Probable G-protein coupled receptor 83 Human genes 0.000 claims 2
- 102100035920 Probable hydrolase PNKD Human genes 0.000 claims 2
- 101710175990 Probable hydrolase PNKD Proteins 0.000 claims 2
- 101710165549 Probable inactive glycosyltransferase 25 family member 3 Proteins 0.000 claims 2
- 102100039022 Propionyl-CoA carboxylase alpha chain, mitochondrial Human genes 0.000 claims 2
- 102100029200 Prostate and breast cancer overexpressed gene 1 protein Human genes 0.000 claims 2
- 102100025781 RING-type E3 ubiquitin-protein ligase PPIL2 Human genes 0.000 claims 2
- 102100029580 RNA exonuclease 1 homolog Human genes 0.000 claims 2
- 102100023750 RNA polymerase II elongation factor ELL2 Human genes 0.000 claims 2
- 102100027478 RNA-binding protein 25 Human genes 0.000 claims 2
- 102100023535 RRP12-like protein Human genes 0.000 claims 2
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 claims 2
- 102100027611 Rho-related GTP-binding protein RhoB Human genes 0.000 claims 2
- 102100021459 Ribosome biogenesis protein NSA2 homolog Human genes 0.000 claims 2
- 101710101739 Ribosome biogenesis protein NSA2 homolog Proteins 0.000 claims 2
- 102100029991 S-formylglutathione hydrolase Human genes 0.000 claims 2
- 102100028663 SH3 domain-binding glutamic acid-rich-like protein 2 Human genes 0.000 claims 2
- 108091006207 SLC-Transporter Proteins 0.000 claims 2
- 102000037054 SLC-Transporter Human genes 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 102100029666 Serine/arginine-rich splicing factor 2 Human genes 0.000 claims 2
- 102100025352 Serine/threonine-protein kinase MRCK alpha Human genes 0.000 claims 2
- 102100031398 Serine/threonine-protein kinase Nek9 Human genes 0.000 claims 2
- 102100032015 Serine/threonine-protein kinase tousled-like 1 Human genes 0.000 claims 2
- 102100037221 Serologically defined colon cancer antigen 8 Human genes 0.000 claims 2
- 101710111739 Serologically defined colon cancer antigen 8 Proteins 0.000 claims 2
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims 2
- 102000006633 Sodium-Bicarbonate Symporters Human genes 0.000 claims 2
- 102100030684 Sphingosine-1-phosphate phosphatase 1 Human genes 0.000 claims 2
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 claims 2
- 108010039445 Stem Cell Factor Proteins 0.000 claims 2
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 claims 2
- 102100034704 THUMP domain-containing protein 1 Human genes 0.000 claims 2
- 102100035260 TSC22 domain family protein 3 Human genes 0.000 claims 2
- 102100030785 Tectonic-3 Human genes 0.000 claims 2
- 108010057966 Thyroid Nuclear Factor 1 Proteins 0.000 claims 2
- 102100024605 Torsin-4A Human genes 0.000 claims 2
- 102100022607 Trafficking protein particle complex subunit 6A Human genes 0.000 claims 2
- 101710105081 Trafficking protein particle complex subunit 6A Proteins 0.000 claims 2
- 102100033710 Transmembrane protein 203 Human genes 0.000 claims 2
- 102100040418 Tumor protein D52 Human genes 0.000 claims 2
- 101710190247 Tumor protein D52 Proteins 0.000 claims 2
- 102100026736 Two pore channel protein 1 Human genes 0.000 claims 2
- 102100039284 UPF0686 protein C11orf1 Human genes 0.000 claims 2
- 102100029449 WD repeat-containing protein 61 Human genes 0.000 claims 2
- 201000011032 Werner Syndrome Diseases 0.000 claims 2
- 102100028499 Zinc finger matrin-type protein 1 Human genes 0.000 claims 2
- 102100025295 Zinc finger protein 280C Human genes 0.000 claims 2
- 102100034646 Zinc finger protein 547 Human genes 0.000 claims 2
- 101710143383 Zinc finger protein 547 Proteins 0.000 claims 2
- 108010080146 androgen receptors Proteins 0.000 claims 2
- 108010057167 dimethylaniline monooxygenase (N-oxide forming) Proteins 0.000 claims 2
- 108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 claims 2
- 201000004510 glycogen storage disease VI Diseases 0.000 claims 2
- 102000028718 growth factor binding proteins Human genes 0.000 claims 2
- 108091009353 growth factor binding proteins Proteins 0.000 claims 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 claims 2
- 210000000633 nuclear envelope Anatomy 0.000 claims 2
- 108010003218 periaxin Proteins 0.000 claims 2
- 102000004593 periaxin Human genes 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102100022383 snRNA-activating protein complex subunit 5 Human genes 0.000 claims 2
- 102100025028 tRNA (guanine-N(7)-)-methyltransferase Human genes 0.000 claims 2
- 102100035305 von Willebrand factor A domain-containing protein 5B2 Human genes 0.000 claims 2
- 108010049926 Acetate-CoA ligase Proteins 0.000 claims 1
- 102100035709 Acetyl-coenzyme A synthetase, cytoplasmic Human genes 0.000 claims 1
- 101710159080 Aconitate hydratase A Proteins 0.000 claims 1
- 101710159078 Aconitate hydratase B Proteins 0.000 claims 1
- 102000003829 Adenylate kinase 2 Human genes 0.000 claims 1
- 108090000115 Adenylate kinase 2 Proteins 0.000 claims 1
- 101000640990 Arabidopsis thaliana Tryptophan-tRNA ligase, chloroplastic/mitochondrial Proteins 0.000 claims 1
- 241000271566 Aves Species 0.000 claims 1
- 102100025442 Biorientation of chromosomes in cell division protein 1 Human genes 0.000 claims 1
- 101150060120 C1qbp gene Proteins 0.000 claims 1
- 108010009575 CD55 Antigens Proteins 0.000 claims 1
- 101710150575 CMP-sialic acid transporter Proteins 0.000 claims 1
- 102100029930 CST complex subunit STN1 Human genes 0.000 claims 1
- 108050009449 CST complex subunit Stn1 Proteins 0.000 claims 1
- 102100025462 Calpain-12 Human genes 0.000 claims 1
- 108050003161 Calpain-12 Proteins 0.000 claims 1
- 101710167917 Carbonic anhydrase 2 Proteins 0.000 claims 1
- 102100024633 Carbonic anhydrase 2 Human genes 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108090000613 Cathepsin S Proteins 0.000 claims 1
- 102100025828 Centromere protein C Human genes 0.000 claims 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 claims 1
- 108010014231 Chemokine CXCL9 Proteins 0.000 claims 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 1
- 102100021903 Cysteine protease ATG4B Human genes 0.000 claims 1
- 102000015208 Cytochrome P450 Family 3 Human genes 0.000 claims 1
- 108010064435 Cytochrome P450 Family 3 Proteins 0.000 claims 1
- 108010033174 Deoxycytidine kinase Proteins 0.000 claims 1
- 102100037124 Developmental pluripotency-associated 5 protein Human genes 0.000 claims 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims 1
- 102100025699 Dual specificity protein phosphatase CDC14B Human genes 0.000 claims 1
- 102000005233 Eukaryotic Initiation Factor-4E Human genes 0.000 claims 1
- 108060002636 Eukaryotic Initiation Factor-4E Proteins 0.000 claims 1
- 101710083182 Fatty acid-binding protein 1 Proteins 0.000 claims 1
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 claims 1
- 101710189565 Fatty acid-binding protein, liver-type Proteins 0.000 claims 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 1
- 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 claims 1
- 108010080982 Formate-tetrahydrofolate ligase Proteins 0.000 claims 1
- 102000034286 G proteins Human genes 0.000 claims 1
- 101710117710 GTPase activating protein 1 Proteins 0.000 claims 1
- 108010001517 Galectin 3 Proteins 0.000 claims 1
- 102100034004 Gamma-adducin Human genes 0.000 claims 1
- 102000004038 Glia Maturation Factor Human genes 0.000 claims 1
- 108090000495 Glia Maturation Factor Proteins 0.000 claims 1
- 102100041013 Glia maturation factor beta Human genes 0.000 claims 1
- 102000011714 Glycine Receptors Human genes 0.000 claims 1
- 108010076533 Glycine Receptors Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102100032489 Heat shock 70 kDa protein 13 Human genes 0.000 claims 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 claims 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 claims 1
- 108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 claims 1
- 102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 claims 1
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 claims 1
- 101710196680 Histone-lysine N-methyltransferase NSD2 Proteins 0.000 claims 1
- 101000934628 Homo sapiens Biorientation of chromosomes in cell division protein 1 Proteins 0.000 claims 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 1
- 101000914241 Homo sapiens Centromere protein C Proteins 0.000 claims 1
- 101000740725 Homo sapiens Complement component 1 Q subcomponent-binding protein, mitochondrial Proteins 0.000 claims 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 1
- 101000753468 Homo sapiens Cysteine protease ATG4B Proteins 0.000 claims 1
- 101000886250 Homo sapiens Death-associated protein 1 Proteins 0.000 claims 1
- 101000881848 Homo sapiens Developmental pluripotency-associated 5 protein Proteins 0.000 claims 1
- 101000932592 Homo sapiens Dual specificity protein phosphatase CDC14B Proteins 0.000 claims 1
- 101000608757 Homo sapiens Galectin-3 Proteins 0.000 claims 1
- 101000799011 Homo sapiens Gamma-adducin Proteins 0.000 claims 1
- 101001039387 Homo sapiens Glia maturation factor beta Proteins 0.000 claims 1
- 101000585315 Homo sapiens Glutaminyl-peptide cyclotransferase Proteins 0.000 claims 1
- 101001016638 Homo sapiens Heat shock 70 kDa protein 13 Proteins 0.000 claims 1
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 claims 1
- 101000634048 Homo sapiens Histone-lysine N-methyltransferase NSD2 Proteins 0.000 claims 1
- 101001006878 Homo sapiens Kelch-like protein 24 Proteins 0.000 claims 1
- 101001063463 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 4 Proteins 0.000 claims 1
- 101000985328 Homo sapiens Methenyltetrahydrofolate cyclohydrolase Proteins 0.000 claims 1
- 101000990528 Homo sapiens Methyltransferase-like protein 17, mitochondrial Proteins 0.000 claims 1
- 101000986821 Homo sapiens P2Y purinoceptor 4 Proteins 0.000 claims 1
- 101000829538 Homo sapiens Polypeptide N-acetylgalactosaminyltransferase 15 Proteins 0.000 claims 1
- 101001068552 Homo sapiens Proline-rich protein 15-like protein Proteins 0.000 claims 1
- 101000705759 Homo sapiens Proteasome activator complex subunit 2 Proteins 0.000 claims 1
- 101000959489 Homo sapiens Protein AF-9 Proteins 0.000 claims 1
- 101001122470 Homo sapiens Protein orai-2 Proteins 0.000 claims 1
- 101000988229 Homo sapiens Protocadherin gamma-A12 Proteins 0.000 claims 1
- 101000591312 Homo sapiens Putative MORF4 family-associated protein 1-like protein UPP Proteins 0.000 claims 1
- 101001061703 Homo sapiens RNA exonuclease 1 homolog Proteins 0.000 claims 1
- 101000580720 Homo sapiens RNA-binding protein 25 Proteins 0.000 claims 1
- 101001077488 Homo sapiens RNA-binding protein Raly Proteins 0.000 claims 1
- 101000823203 Homo sapiens RUN domain-containing protein 3B Proteins 0.000 claims 1
- 101001106816 Homo sapiens Rab11 family-interacting protein 2 Proteins 0.000 claims 1
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 claims 1
- 101000587430 Homo sapiens Serine/arginine-rich splicing factor 2 Proteins 0.000 claims 1
- 101000637839 Homo sapiens Serine/threonine-protein kinase tousled-like 1 Proteins 0.000 claims 1
- 101000806155 Homo sapiens Short-chain dehydrogenase/reductase 3 Proteins 0.000 claims 1
- 101000585484 Homo sapiens Signal transducer and activator of transcription 1-alpha/beta Proteins 0.000 claims 1
- 101000658110 Homo sapiens Synaptotagmin-like protein 2 Proteins 0.000 claims 1
- 101000809797 Homo sapiens Thymidylate synthase Proteins 0.000 claims 1
- 101001071076 Homo sapiens Translation factor GUF1, mitochondrial Proteins 0.000 claims 1
- 101000723758 Homo sapiens Zinc finger protein 25 Proteins 0.000 claims 1
- 101000830183 Homo sapiens tRNA (guanine-N(7)-)-methyltransferase Proteins 0.000 claims 1
- 101710176225 Kallikrein-8 Proteins 0.000 claims 1
- 102100027794 Kelch-like protein 24 Human genes 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 101710174259 Leucine-rich repeat-containing G-protein coupled receptor 4 Proteins 0.000 claims 1
- 102100028687 Methenyltetrahydrofolate cyclohydrolase Human genes 0.000 claims 1
- 108010010685 Methenyltetrahydrofolate cyclohydrolase Proteins 0.000 claims 1
- 102100030508 Methyltransferase-like protein 17, mitochondrial Human genes 0.000 claims 1
- 102100021769 Mitochondrial 2-oxoglutarate/malate carrier protein Human genes 0.000 claims 1
- 108010006519 Molecular Chaperones Proteins 0.000 claims 1
- 241000713333 Mouse mammary tumor virus Species 0.000 claims 1
- 102100035384 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 2 Human genes 0.000 claims 1
- 101710098657 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 2 Proteins 0.000 claims 1
- 102000007999 Nuclear Proteins Human genes 0.000 claims 1
- 108010089610 Nuclear Proteins Proteins 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 108010049358 Oncogene Protein p65(gag-jun) Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102100028070 P2Y purinoceptor 4 Human genes 0.000 claims 1
- 102100033950 Proline-rich protein 15-like protein Human genes 0.000 claims 1
- 102100031299 Proteasome activator complex subunit 2 Human genes 0.000 claims 1
- 102100039686 Protein AF-9 Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102100027134 Protein orai-2 Human genes 0.000 claims 1
- 102100029264 Protocadherin gamma-A12 Human genes 0.000 claims 1
- 102100034096 Putative MORF4 family-associated protein 1-like protein UPP Human genes 0.000 claims 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 claims 1
- 101710089258 RNA-binding motif protein 25 Proteins 0.000 claims 1
- 101710105008 RNA-binding protein Proteins 0.000 claims 1
- 101710205948 RNA-binding protein 25 Proteins 0.000 claims 1
- 102100025052 RNA-binding protein Raly Human genes 0.000 claims 1
- 102100022666 RUN domain-containing protein 3B Human genes 0.000 claims 1
- 101710084153 Rab11 family-interacting protein 2 Proteins 0.000 claims 1
- 108050004017 Ras GTPase-activating protein 1 Proteins 0.000 claims 1
- 102100025234 Receptor of activated protein C kinase 1 Human genes 0.000 claims 1
- 108010044157 Receptors for Activated C Kinase Proteins 0.000 claims 1
- 108091006417 SLC25A11 Proteins 0.000 claims 1
- 108091006540 SLC35A1 Proteins 0.000 claims 1
- 108091006262 SLC4A4 Proteins 0.000 claims 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 101710123513 Serine/arginine-rich splicing factor 2 Proteins 0.000 claims 1
- 101710098564 Serine/threonine-protein kinase tousled-like 1 Proteins 0.000 claims 1
- 102100037857 Short-chain dehydrogenase/reductase 3 Human genes 0.000 claims 1
- 108010087132 Sodium-Bicarbonate Symporters Proteins 0.000 claims 1
- 108010019965 Spectrin Proteins 0.000 claims 1
- 102000005890 Spectrin Human genes 0.000 claims 1
- 101000720079 Stichodactyla helianthus DELTA-stichotoxin-She4a Proteins 0.000 claims 1
- 102100035007 Synaptotagmin-like protein 2 Human genes 0.000 claims 1
- 108010022394 Threonine synthase Proteins 0.000 claims 1
- 102000005497 Thymidylate Synthase Human genes 0.000 claims 1
- 102100038618 Thymidylate synthase Human genes 0.000 claims 1
- 102100033095 Translation factor GUF1, mitochondrial Human genes 0.000 claims 1
- 108010088412 Trefoil Factor-1 Proteins 0.000 claims 1
- 102100039175 Trefoil factor 1 Human genes 0.000 claims 1
- 102000002501 Tryptophan-tRNA Ligase Human genes 0.000 claims 1
- LFTYTUAZOPRMMI-NESSUJCYSA-N UDP-N-acetyl-alpha-D-galactosamine Chemical compound O1[C@H](CO)[C@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1O[P@](O)(=O)O[P@](O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-NESSUJCYSA-N 0.000 claims 1
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 claims 1
- 102000018390 Ubiquitin-Specific Proteases Human genes 0.000 claims 1
- 108010066496 Ubiquitin-Specific Proteases Proteins 0.000 claims 1
- 102000013814 Wnt Human genes 0.000 claims 1
- 108050003627 Wnt Proteins 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 102100028393 Zinc finger protein 25 Human genes 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims 1
- 230000000599 auto-anti-genic effect Effects 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 1
- 102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 210000001589 microsome Anatomy 0.000 claims 1
- 210000003470 mitochondria Anatomy 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000004940 nucleus Anatomy 0.000 claims 1
- 108010023005 oxoglutarate translocator Proteins 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 108010078587 pseudouridylate synthetase Proteins 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 101710112043 tRNA (guanine-N(7)-)-methyltransferase Proteins 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 84
- 238000004364 calculation method Methods 0.000 abstract description 4
- 210000002700 urine Anatomy 0.000 description 73
- 239000000439 tumor marker Substances 0.000 description 46
- 210000001519 tissue Anatomy 0.000 description 43
- 206010005003 Bladder cancer Diseases 0.000 description 39
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 39
- 201000005112 urinary bladder cancer Diseases 0.000 description 38
- 239000003550 marker Substances 0.000 description 34
- 239000013615 primer Substances 0.000 description 33
- 238000003753 real-time PCR Methods 0.000 description 32
- 230000003211 malignant effect Effects 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 24
- 238000002493 microarray Methods 0.000 description 24
- 230000035945 sensitivity Effects 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 108020004635 Complementary DNA Proteins 0.000 description 20
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 238000009396 hybridization Methods 0.000 description 20
- 238000010804 cDNA synthesis Methods 0.000 description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 239000012634 fragment Substances 0.000 description 13
- 239000002987 primer (paints) Substances 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000003321 amplification Effects 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000003757 reverse transcription PCR Methods 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 102100031780 Endonuclease Human genes 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 108091060211 Expressed sequence tag Proteins 0.000 description 7
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 108010006785 Taq Polymerase Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108091093088 Amplicon Proteins 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000005068 bladder tissue Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 208000006750 hematuria Diseases 0.000 description 5
- 238000010208 microarray analysis Methods 0.000 description 5
- 238000000611 regression analysis Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000010224 classification analysis Methods 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000012775 microarray technology Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000003443 bladder cell Anatomy 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 238000002790 cross-validation Methods 0.000 description 3
- 238000000326 densiometry Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 238000002574 cystoscopy Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000011223 gene expression profiling Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000003741 urothelium Anatomy 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 108020004513 Bacterial RNA Proteins 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 102100036961 Nuclear mitotic apparatus protein 1 Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 101150107801 Top2a gene Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108010036112 nuclear matrix protein 22 Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G06F19/345—
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Definitions
- This invention relates to detection of cancer. Specifically, the invention relates to the use of markers for the detection of bladder cancer. More specifically, this invention relates to use of an under-expressed marker in combination with at least one other marker for the detection of bladder cancer.
- cytology is known to be only about 75% sensitive for detecting invasive bladder cancer and only about 25% sensitive for detecting superficial bladder cancer (Lotan and Roehrborn, Urology 61, 109-118 (2003)).
- Specific cancer markers for cancer in urine can provide a valuable approach for the early diagnosis of cancer, leading to early treatment and improved prognosis.
- Specific cancer markers also provide a means for monitoring disease progression, enabling the efficacy of surgical, radiotherapeutic and chemotherapeutic treatments to be monitored.
- cystoscopy accompanied by histology of biopsied lesions.
- this technique is time consuming, invasive and its sensitivity is only approximately 90%, meaning that about 10 percent of cancers are not detected using these methods.
- urine cytology which detects exfoliated malignant cells microscopically, is the current preferred method.
- cytology has a specificity of about 95%, it has poor sensitivity (9-25%) for low-grade lesions, is extremely dependent on sample quality and suffers from high inter-observer variability.
- NMP22 which detects a specific nuclear matrix protein, has a sensitivity of 47-87% and a specificity of 58-91%.
- One drawback associated with urine testing is that individual marker levels can vary significantly with: (i) different urine collection methods (catheterised, voided, urine pellets); (ii) the diurnal timing of urine sampling; (iii) the point of sampling during voiding (e.g. midstream vs end sample); and (iv) urine concentration associated with varying fluid intake, kidney function or diseases that affect plasma volume. These variations have the potential to lead to false positive and false negative tests. Although some of this variation can be reduced using strict standard operating procedures, patient compliance with these procedures can be unreliable. The effect of varying urine concentration can, in some instances, be accounted for by assessing marker levels relative to urinary creatinine, however, this increases the cost and complexity of testing, particularly when sample preparation or storage methods differ for marker detection and creatinine measurement.
- This invention provides further methods, devices and kits based on markers, specifically ratios, regression or classification analysis of bladder cancer markers, to aid in the detection and diagnosis of bladder cancer.
- the present invention provides for a method for determining the presence of a cancer in a subject, comprising:
- Step (c) can be preformed by determining the ratio of expression of said TMs, or by performing regression or classification analysis on the TM expression levels.
- the TM can be a BTM.
- the cancer to be detected can be bladder cancer, and in certain embodiments at least one of the TMs is an over-expressed BTM.
- the over-expressed BTM may be selected from the group outlined in FIG. 11 or FIG. 12 .
- At least one under-expressed TM is a BTM selected from the group outlined in FIG. 3 or FIG. 4 .
- the step of detecting is carried out by detecting over expression of BTM mRNA, a BTM protein, or a BTM peptide.
- the sample can be any one of biopsy, blood, serum, peritoneal washes, cerebrospinal fluid, urine and stool samples
- the present invention also provides for a device for detecting a TM, comprising:
- a detector associated with said substrate capable of detecting a TM associated with said capture reagent, wherein the TM is an under-expressed TM.
- the TM can be a BTM.
- the TM capture reagent can be an oligonucleotide or an antibody.
- the TM can be a BTM selected from the group outlined in FIG. 3 or FIG. 4 .
- the present invention also provides for a kit for determining the presence of a cancer in a subject, comprising:
- At least two TM capture reagents wherein at least one TM is an under-expressed TM;
- the TM can be a BTM.
- the TM capture reagent may be a TM-specific oligonucleotide or a TM-specific antibody.
- the TM detected by the kit may be a BTM selected from the group outlined in FIG. 3 or FIG. 4 .
- At least one of the TMs detected by the kit may be an over-expressed TM or an over-expressed BTM.
- the over-expressed BTM may be selected from the group outlined in FIG. 11 or FIG. 12 .
- FIG. 1 depicts a table showing the characteristics of urine samples used in the qPCR analyses.
- FIG. 2 depicts a table of primers and oligonucleotide probes of markers for qPCR analysis of bladder cancer according to the present invention.
- FIG. 3 depicts a table of under-expressing bladder tumour markers identified using microarray methods on samples of bladder cancer.
- FIG. 4 depicts a table of under-expressing bladder tumour markers identified using microarray methods on samples of bladder cancer that have insignificant expression in whole blood, but high expression in normal bladder tissue.
- FIG. 5 depicts box and whisker plots showing the ratios of three bladder transitional cell carcinoma (TCC) markers (HoxA13, IGFBP5, and MDK) with the under expressing marker LTB4DH for urine samples from patients with either non-malignant urological disease or TCC.
- TCC transitional cell carcinoma
- the boxes define the 25 th , 50 th and 75 th percentiles and the horizontal bars mark the adjacent values. Outliers are shown by circles.
- the unfilled boxes represent samples from non-malignant disease controls and the shaded boxes represent samples from patients with TCC.
- FIGS. 6A-6B show examples of the sensitivities and specificities of TCC detection for tests that include LTB4DH.
- FIG. 6A single tests
- FIG. 6B combination tests using LTB4DH and two of the three markers HoxA13, IGFBP5, and MDK.
- FIGS. 7A-7C show ROC curves for the sensitivity and specificity of detection of TCC in urine samples using ratios that include LTB4DH.
- FIG. 7A IGFBP5/LTB4DH
- FIG. 7B MDK/LT4BDH
- FIG. 7C HoxA13/LTB4DH.
- FIGS. 8A-8F show scatter plots for combination tests, FIGS. 8A-C using LTB4DH and two of the three markers HoxA13, IGFBP5, and MDK, and FIGS. 8D-F repeated using BAG1 for LTB4DH.
- FIG. 8A MDK/LTB4DH and IGFBP5/LTB4DH;
- FIG. 8B MDK/LTB4DH and HoxA13/LTB4DH
- FIG. 8C IGFBP5/LTB4DH and HoxA13/LTB4DH;
- FIG. 8D MDK/BAG1 and IGFBP5/BAG1;
- FIG. 8E MDK/BAG1 and HoxA13/BAG1;
- FIG. 8F IGFBP5/BAG1 and HoxA13/BAG1.
- FIGS. 9A-9B show scatter plots showing the correlation between ⁇ Ct for IGFBP5 and ⁇ Ct ratios for IGFBP5/LTB4DH and urine creatinine concentration.
- FIG. 9A Urine samples from patients with TCC
- FIG. 9B Urine samples from patients with non-malignant disease
- FIGS. 10A-10F depict self-self scatter plots showing the distribution of voided and catheterised urine samples from TCC patients analysed using the bladder tumour markers MDK, IGFBP5 and HoxA13 alone or in ratios with LTB4DH.
- FIG. 10A depicts a self-self scatter plot for MDK.
- FIG. 10B depicts a self-self scatter plot for MDK/LTB4DH.
- FIG. 10C depicts a self-self scatter plot for IGFBP5.
- FIG. 10D depicts a self-self scatter plot for IGFB5/LTB4DH.
- FIG. 10E depicts a self-self scatter plot for HoxA13.
- FIG. 10F depicts a self-self scatter plot for HoxA13/LTB4DH
- FIG. 11 shows known over-expressed markers from invasive bladder tumours.
- FIG. 12 shows known over-expressed markers from superficial bladder tumours.
- FIG. 13 shows the clinical characteristics of low grade TCC samples and controls used in ROC curve analysis.
- FIG. 14 shows the results of a ROC Curve analysis. Illustration of the increased test accuracy obtained when LTB4DH is used in ratios with HoxA13 and IGFBP5.
- FIG. 15 shows the results of a Linear Discriminate Analysis of BTMs, with and without LTB4DH, for the detection of TCC.
- markers means a molecule that is associated quantitatively or qualitatively with the presence of a biological phenomenon.
- markers include a polynucleotide, such as a gene, gene fragment, RNA, or RNA fragment; or a gene product, including a polypeptide such as a peptide, oligopeptide protein or protein fragment; or related metabolites, by products or other identifying molecules, such as antibodies or antibody fragments whether related directly or indirectly to a mechanism underlying the phenomenon.
- the markers of the invention include the nucleotide sequences (e.g. GenBank sequences) as disclosed herein, in particular the full length sequences, any coding sequences, non-coding sequences and fragments, or any compliments thereof, and any measurable marker thereof as defined above.
- sensitivity means the proportion of individuals with the disease who test (by the model) positive. Thus, increased sensitivity means fewer false negative test results.
- expression includes production of polynucleotides and polypeptides, in particular, the production of RNA (e.g., mRNA) from a gene or portion of a gene, and includes the production of a polypeptide encoded by an RNA or gene or portion of a gene, and includes appearance of a detectable material associated with expression.
- RNA e.g., mRNA
- formation of a complex for example, from a polypeptide-polypeptide interaction, polypeptide-nucleotide interaction, or the like, is included within the scope of the term “expression”.
- binding of a binding ligand such as a hybridization probe or antibody
- a gene or other polynucleotide such as a gene or other polynucleotide, a polypeptide or a protein fragment
- the density of a spot on a microarray, on a hybridization blot such as a Northern blot, or on an immunoblot, such as a Western blot, or on a bead array, or by PCR analysis is included within the term “expression” of the underlying biological molecule.
- over expression is used where the expression of a marker in one cell, or cell type, is greater than that of another equivalent cell, or cell type.
- under expression is used where the expression of a marker in one cell, or cell type, is less than that of another equivalent cell, or cell type.
- TM tumor marker
- TM family member means a marker that is associated with a particular cancer.
- TM also includes combinations of individual markers, whose combination improves the sensitivity and specificity of detecting cancer. It is to be understood that the term TM does not require that the marker be specific only for a particular tumour. Rather, expression of TM can be altered in other types of cells, diseased cells, tumours, including malignant tumours.
- a TM can be identified by extracting RNA from a tissue sample from a patient suspected of having bladder cancer, applying the RNA or cDNA copy to a microarray having a number of oligonucleotides thereon, permitting the sample RNA to hybridize to the oligonucleotides on the array, and then quantifying the level of measured RNA bound to the each array spot.
- a marker is considered to be a under expressing TM if its presence is below a threshold of at least about 1.2 times that found in normal, non-malignant tissue using microarray methods. Alternatively, the threshold can be below about 2 times normal, about 3 times less than normal, 4 times or even about 5 times less than normal. By “normal” we mean less than the 90 th percentile of the normal population.
- normal can mean a level of presence of the 95 th percentile (i.e., about 2 Standard Deviations (SD) from the mean), and in other cases, less than about 97.5 th percentile (i.e., about 3 SD) or the 99 th percentile.
- SD Standard Deviations
- under expressing TM means a marker that shows lower expression in bladder tumours than in non-malignant bladder tissue.
- over expressing TM means a marker that shows higher expression in bladder tumours than in non-malignant tissue.
- BTM or “bladder tumour marker” or “BTM family member” means a TM that is associated with bladder cancer.
- BTM also includes combinations of individual markers, whose combination improves the sensitivity and specificity of detecting bladder cancer. It is to be understood that the term BTM does not require that the marker be specific only for bladder tumours. Rather, expression of BTM can be altered in other types of cells, diseased cells, tumours, including malignant tumours.
- under expressing BTM means a marker that shows lower expression in bladder tumours than in non-malignant bladder tissue.
- over expressing BTM means a marker that shows higher expression in bladder tumours than in non-malignant tissue.
- qPCR means quantitative polymerase chain reaction.
- qPCR or “QPCR” refers to quantitative polymerase chain reaction as described, for example, in PCR Technique: Quantitative PCR, J. W. Larrick, ed., Eaton Publishing, 1997, and A-Z of Quantitative PCR, S. Bustin, ed., IUL Press, 2004.
- TCC means transitional cell carcinoma of the bladder. TCCs constitute ⁇ 95% of all bladder cancers.
- antibodies and like terms refer to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. These include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fc, Fab, Fab′, and Fab2 fragments, and a Fab expression library. Antibody molecules relate to any of the classes IgG, IgM, IgA, IgE, and IgD, which differ from one another by the nature of heavy chain present in the molecule. These include subclasses as well, such as IgG1, IgG2, and others.
- the light chain may be a kappa chain or a lambda chain.
- Reference herein to antibodies includes a reference to all classes, subclasses, and types. Also included are chimeric antibodies, for example, monoclonal antibodies or fragments thereof that are specific to more than one source, e.g., a mouse or human sequence. Further included are camelid antibodies, shark antibodies or nanobodies.
- cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by abnormal or unregulated cell growth. Cancer and cancer pathology can be associated, for example, with metastasis, interference with the normal functioning of neighbouring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, neoplasia, premalignancy, malignancy, invasion of surrounding or distant tissues or organs, such as lymph nodes, etc.
- tumor refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
- microarray refers to an ordered or unordered arrangement of capture agents, preferably polynucleotides (e.g., probes) or polypeptides on a substrate. See, e.g., Microarray Analysis, M. Schena, John Wiley & Sons, 2002; Microarray Biochip Technology, M. Schena, ed., Eaton Publishing, 2000; Guide to Analysis of DNA Microarray Data, S. Knudsen, John Wiley & Sons, 2004; and Protein Microarray Technology, D. Kambhampati, ed., John Wiley & Sons, 2004.
- oligonucleotide refers to a polynucleotide, typically a probe or primer, including, without limitation, single-stranded deoxyribonucleotides, single- or double-stranded ribonucleotides, RNA: DNA hybrids, and double-stranded DNAs. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are often synthesized by chemical methods, for example using automated oligonucleotide synthesizers that are commercially available, or by a variety of other methods, including in vitro expression systems, recombinant techniques, and expression in cells and organisms.
- polynucleotide when used in the singular or plural, generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
- triple-stranded regions comprising RNA or DNA or both RNA and DNA.
- mRNAs RNAs, cDNAs, and genomic DNAs, and any fragments thereof.
- the term includes DNAs and RNAs that contain one or more modified bases, such as tritiated bases, or unusual bases, such as inosine.
- the polynucleotides of the invention can encompass coding or non-coding sequences, or sense or antisense sequences. It will be understood that each reference to a “polynucleotide” or like term, herein, will include the full-length sequences as well as any fragments, derivatives, or variants thereof.
- Polypeptide refers to an oligopeptide, peptide, or protein sequence, or fragment thereof, and to naturally occurring, recombinant, synthetic, or semi-synthetic molecules. Where “polypeptide” is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, “polypeptide” and like terms, are not meant to limit the amino acid sequence to the complete, native amino acid sequence for the full-length molecule.
- “Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridisable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. Additional details and explanation of stringency of hybridization reactions, are found e.g., in Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).
- “Stringent conditions” or “high stringency conditions”, as defined herein, typically: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ a denaturing agent during hybridization, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50% formamide, 5 ⁇ SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 ⁇ , Denhardt's solution, sonicated salmon sperm DNA (50 ⁇ g/ml), 0.1% SDS, and 10% dextran sulfate at
- Modely stringent conditions may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e. g., temperature, ionic strength, and % SDS) less stringent that those described above.
- washing solution and hybridization conditions e. g., temperature, ionic strength, and % SDS
- An example of moderately stringent conditions is overnight incubation at 37° C.
- Blackwell eds., Blackwell Science Inc., 1987; Gene Transfer Vectors for Mammalian Cells, J. M. Miller & M. P. Calos, eds., 1987; Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., 1987; and PCR: The Polymerase Chain Reaction, Mullis et al., eds., 1994.
- TCC transitional cell carcinoma of the bladder
- BTM bladder tumour markers
- the ratios (rather than measuring an absolute level of a marker) identifies a simple gene expression ‘signature’ that typifies bladder cancer cells, and surprisingly is more robust to variations in sampling techniques or urine concentration. Moreover, the combination of an under-expressed marker and an over-expressed marker maximizes the differential between samples from patients and non-malignant controls, increasing the test reliability.
- the under-expressed markers described here have been selected on the basis of (i) strong and consistent down-regulation in TCC, (ii) high expression in normal tissue, and (iii) insignificant expression in whole blood to minimize the risk of false positives in patients presenting with hematuria.
- under-expressed and over-expressed BTMs can be analysed in regression analyses or classification techniques including linear discriminate analysis, and the results of these analyses are also indicative of the presence of bladder cancer.
- the test involves the measuring of at least two TM markers, such as a BTM, in a sample from a patient suspected of having a cancer or at risk of having cancer, wherein at least one of the TMs is an under-expressed TM.
- the ratio of the under-expressed TM and the other TM is indicative of the presence of cancer.
- the second TM can be any TM as known in the art, but preferably is an over-expressed BTM.
- FIG. 3 shows a number of under-expressed markers suitable for use in the present invention.
- the test is best preformed using an under-expressed TM in combination with an over-expressed TM.
- Any over-expressed TM can be used, for example.
- Known over expressed BTMs identified from invasive bladder tumours (defined here as tumours ⁇ stage 1), are outlined in FIG. 11 , and over-expressed BTMs identified from superficial bladder tumours (defined here as Stage Ta and Tis tumours) are shown in FIG. 12 .
- preferred under-expressed BTMs for use in the present invention are ones that are not significantly elevated in whole blood, and are present in sufficiently high copy numbers in both tumour cells and non-malignant bladder cells.
- Preferred under-expressed BTMs are outlined in FIG. 4 .
- Cancer markers can be detected in a sample using any suitable technique, and can include, but are not limited to, oligonucleotide probes, qPCR or antibodies raised against cancer markers.
- sample to be tested is not restricted to a sample of the tissue suspected of being a tumour.
- the marker may be secreted into the serum, sloughed from cell membranes, released from lysed cells or associated with cells lost into the urine. Therefore, a sample can include any bodily sample, and includes biopsies, blood, serum, peritoneal washes, cerebrospinal fluid, urine and stool samples.
- the present invention is not restricted to the detection of cancer in humans, but is suitable for the detection of cancer in any animal, including, but not limited to dogs, cats, horses, cattle, sheep, deer, pigs and any other animal known to get cancer.
- TMs TMs
- ratios between high and low expressing BTM family members are determined. These ratios are used to predict the presence or absence cancer.
- the high and low expressing TMs are used in regression or classification analyses. The results of these analyses are also used to predict the presence or absence cancer.
- Quantitative PCR can be carried out on tumour samples, on serum, plasma and urine samples using BTM specific primers and probes.
- the amount of product formed in a PCR reaction correlates with the amount of starting template.
- Quantification of the PCR product can be carried out by stopping the PCR reaction when it is in log phase, before reagents become limiting.
- PCR products are then electrophoresed in agarose or polyacrylamide gels, stained with ethidium bromide or a comparable DNA stain, and the intensity of staining measured by densitometry.
- the progression of a PCR reaction can be measured using PCR machines such as the Applied Biosystems' Prism 7000 or the Roche LightCycler which measure product accumulation in real-time.
- Real-time PCR measures either the fluorescence of DNA intercalating dyes such as Sybr Green into the synthesized PCR product, or the fluorescence released by a reporter molecule when cleaved from a quencher molecule; the reporter and quencher molecules are incorporated into an oligonucleotide probe which hybridizes to the target DNA molecule following DNA strand extension from the primer oligonucleotides.
- the oligonucleotide probe is displaced and degraded by the enzymatic action of the Taq polymerase in the next PCR cycle, releasing the reporter from the quencher molecule.
- Scorpion® the probe is covalently linked to the primer.
- RT-PCR Reverse Transcription PCR
- RT-PCR can be used to compare RNA levels in different sample populations, in normal and tumour tissues, with or without drug treatment, to characterize patterns of expression, to discriminate between closely related RNAs, and to analyze RNA structure.
- RNA is typically total RNA isolated from human tumours or tumour cell lines, and corresponding normal tissues or cell lines, respectively.
- the starting material is typically total RNA isolated from human tumours or tumour cell lines, and corresponding normal tissues or cell lines, respectively.
- RNA can be isolated from a variety of samples, such as tumour samples from breast, lung, colon (e.g., large bowel or small bowel), colorectal, gastric, esophageal, anal, rectal, prostate, brain, liver, kidney, pancreas, spleen, thymus, testis, ovary, uterus, bladder etc., tissues, from primary tumours, or tumour cell lines, and from pooled samples from healthy donors.
- RNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g., formalin-fixed) tissue samples.
- the first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction.
- the two most commonly used reverse transcriptases are avian myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukaemia virus reverse transcriptase (MMLV-RT).
- AMV-RT avian myeloblastosis virus reverse transcriptase
- MMLV-RT Moloney murine leukaemia virus reverse transcriptase
- the reverse transcription step is typically primed using specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling.
- extracted RNA can be reverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, CA, USA), following the manufacturer's instructions.
- the derived cDNA can then be used as a template in the subsequent PCR reaction.
- the PCR step can use a variety of thermostable DNA-dependent DNA polymerases, it typically employs the Taq DNA polymerase, which has a 5′-3′ nuclease activity but lacks a 3′-5′ proofreading endonuclease activity.
- TaqMan (q) PCR typically utilizes the 5′ nuclease activity of Taq or Tth polymerase to hydrolyze a hybridization probe bound to its target amplicon, but any enzyme with equivalent 5′ nuclease activity can be used.
- oligonucleotide primers are used to generate an amplicon typical of a PCR reaction.
- a third oligonucleotide, or probe is designed to detect nucleotide sequence located between the two PCR primers.
- the probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe.
- the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner
- the resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore.
- One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.
- TaqMan RT-PCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700 Sequence Detection System (Perkin-Elmer-Applied Biosystems, Foster City, Calif., USA), or Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany)
- the 5′ nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700tam Sequence Detection System.
- the system consists of a thermocycler, laser, charge-coupled device (CCD), camera, and computer.
- the system amplifies samples in a 96-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fibre optics cables for all 96 wells, and detected at the CCD.
- the system includes software for running the instrument and for analyzing the data.
- 5′ nuclease assay data are initially expressed as Ct, or the threshold cycle.
- fluorescence values are recorded during every cycle and represent the amount of product amplified to that point in the amplification reaction. The point when the fluorescent signal is first recorded as statistically significant is the threshold cycle.
- RT-PCR A more recent variation of the RT-PCR technique is the real time quantitative PCR, which measures PCR product accumulation through a dual-labeled fluorigenic probe (i.e., TaqMan probe).
- Real time PCR is compatible both with quantitative competitive PCR and with quantitative comparative PCR.
- the former uses an internal competitor for each target sequence for normalization, while the latter uses a normalization gene contained within the sample, or a housekeeping gene for RT-PCR. Further details are provided, e.g., by Held et al., Genome Research 6: 986-994 (1996).
- PCR primers and probes are designed based upon intron sequences present in the gene to be amplified.
- the first step in the primer/probe design is the delineation of intron sequences within the genes. This can be done by publicly available software, such as the DNA BLAT software developed by Kent, W. J., Genome Res. 12 (4): 656-64 (2002), or by the BLAST software including its variations. Subsequent steps follow well established methods of PCR primer and probe design.
- PCR primer design The most important factors considered in PCR primer design include primer length, melting temperature (Tm), and G/C content, specificity, complementary primer sequences, and 3′ end sequence.
- optimal PCR primers are generally 17-30 bases in length, and contain about 20-80%, such as, for example, about 50-60% G+C bases. Melting temperatures between 50 and 80° C., e.g., about 50 to 70° C., are typically preferred.
- CCPMs Differential expression can also be identified, or confirmed using the microarray technique.
- the expression profile of CCPMs can be measured in either fresh or paraffin-embedded tumour tissue, using microarray technology.
- polynucleotide sequences of interest including cDNAs and oligonucleotides
- the arrayed sequences i.e., capture probes
- specific polynucleotides from cells or tissues of interest i.e., targets.
- the source of RNA typically is total RNA isolated from human tumours or tumour cell lines, and corresponding normal tissues or cell lines.
- RNA can be isolated from a variety of primary tumours or tumour cell lines. If the source of RNA is a primary tumour, RNA can be extracted, for example, from frozen or archived formalin fixed paraffin-embedded (FFPE) tissue samples and fixed (e.g., formalin-fixed) tissue samples, which are routinely prepared and preserved in everyday clinical practice.
- FFPE formalin fixed paraffin-embedded
- PCR amplified inserts of cDNA clones are applied to a substrate.
- the substrate can include up to 1, 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, or 75 nucleotide sequences. In other aspects, the substrate can include at least 10,000 nucleotide sequences.
- the microarrayed sequences, immobilized on the microchip, are suitable for hybridization under stringent conditions.
- the targets for the microarrays can be at least 50, 100, 200, 400, 500, 1000, or 2000 bases in length; or 50-100, 100-200, 100-500, 100-1000, 100-2000, or 500-5000 bases in length.
- the capture probes for the microarrays can be at least 10, 15, 20, 25, 50, 75, 80, or 100 bases in length; or 10-15, 10-20, 10-25, 10-50, 10-75, 10-80, or 20-80 bases in length.
- Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest. Labeled cDNA probes applied to the chip hybridize with specificity to each spot of DNA on the array. After stringent washing to remove non-specifically bound probes, the chip is scanned by confocal laser microscopy or by another detection method, such as a CCD camera. Quantitation of hybridization of each arrayed element allows for assessment of corresponding mRNA abundance. With dual colour fluorescence, separately labeled cDNA probes generated from two sources of RNA are hybridized pairwise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously. An exemplary protocol for this is described in detail in Example 4.
- the miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes.
- Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al., Proc. Natl. Acad. Sci. USA 93 (2): 106-149 (1996)).
- Microarray analysis can be performed by commercially available equipment, following manufacturer's protocols, such as by using the Affymetrix GenChip technology, Illumina microarray technology or Incyte's microarray technology.
- the development of microarray methods for large-scale analysis of gene expression makes it possible to search systematically for molecular markers of cancer classification and outcome prediction in a variety of tumour types.
- RNA isolation can be performed using purification kit, buffer set, and protease from commercial manufacturers, such as Qiagen, according to the manufacturer's instructions. For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini-columns.
- RNA isolation kits include MasterPure Complete DNA and RNA Purification Kit (EPICENTRE (D, Madison, Wis.), and Paraffin Block RNA Isolation Kit (Ambion, Inc.). Total RNA from tissue samples can be isolated using RNA Stat-60 (Tel-Test). RNA prepared from tumour can be isolated, for example, by cesium chloride density gradient centrifugation.
- RNA isolation, purification, primer extension and amplification are given in various published journal articles (for example: T. E. Godfrey et al. J. Molec. Diagnostics 2: 84-91 (2000); K. Specht et al., Am. J. Pathol. 158: 419-29 (2001)).
- a representative process starts with cutting about 10 ⁇ m thick sections of paraffin-embedded tumour tissue samples. The RNA is then extracted, and protein and DNA are removed.
- RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR. Finally, the data are analyzed to identify the best treatment option(s) available to the patient on the basis of the characteristic gene expression pattern identified in the tumour sample examined.
- Immunohistochemistry methods are also suitable for detecting the expression levels of the proliferation markers of the present invention.
- antibodies or antisera preferably polyclonal antisera, and most preferably monoclonal antibodies specific for each marker, are used to detect expression.
- the antibodies can be detected by direct labeling of the antibodies themselves, for example, with radioactive labels, fluorescent labels, hapten labels such as, biotin, or an enzyme such as horse radish peroxidase or alkaline phosphatase.
- unlabeled primary antibody is used in conjunction with a labeled secondary antibody, comprising antisera, polyclonal antisera or a monoclonal antibody specific for the primary antibody.
- Immunohistochemistry protocols and kits are well known in the art and are commercially available.
- Proteomics can be used to analyze the polypeptides present in a sample (e.g., tissue, organism, or cell culture) at a certain point of time.
- proteomic techniques can be used to assess the global changes of polypeptide expression in a sample (also referred to as expression proteomics).
- Proteomic analysis typically includes: (1) separation of individual polypeptides in a sample by 2-D gel electrophoresis (2-D PAGE); (2) identification of the individual polypeptides recovered from the gel, e.g., by mass spectrometry or N-terminal sequencing, and (3) analysis of the data using bioinformatics.
- Proteomics methods are valuable supplements to other methods of gene expression profiling, and can be used, alone or in combination with other methods, to detect the products of the proliferation markers of the present invention.
- RNA or cDNA derived from the test sample binding the nucleic acid probe to a support, and hybridizing under appropriate conditions with RNA or cDNA derived from the test sample (Sambrook, J., E Fritsch, E. and T Maniatis, Molecular Cloning: A Laboratory Manual 3 rd . Cold Spring Harbor Laboratory Press: Cold Spring Harbor (2001)). These methods can be applied to BTM derived from a tumour tissue or fluid sample.
- the RNA or cDNA preparations are typically labeled with a fluorescent or radioactive molecule to enable detection and quantification.
- the hybridizing DNA can be tagged with a branched, fluorescently labeled structure to enhance signal intensity (Nolte, F.
- the supports can be solid, such as nylon or nitrocellulose membranes, or consist of microspheres or beads that are hybridized when in liquid suspension.
- the beads may be magnetic (Haukanes, B-I and Kvam, C., Application of magnetic beads in bioassays.
- hybridization technology is the QuantiGene Plex® assay (Genospectra, Fremont) which combines a fluorescent bead support with branched DNA signal amplification.
- Quantikine® mRNA assay R&D Systems, Minneapolis. Methodology is as described in the manufacturer's instructions. Briefly the assay uses oligonucleotide hybridization probes conjugated to Digoxigenin. Hybridization is detected using anti-Digoxigenin antibodies coupled to alkaline phosphatase in colorometric assays.
- a polyclonal or monoclonal antibody against the BTM is bound to a solid support (Crowther, J. R. The ELISA guidebook. Humana Press: New Jersey (2000); Harlow, E. and Lane, D., Using antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (1999)) or suspension beads. Other methods are known in the art and need not be described herein further.
- Monoclonal antibodies can be hybridoma-derived or selected from phage antibody libraries (Hust M. and Dubel S., Phage display vectors for the in vitro generation of human antibody fragments. Methods Mol Biol. 295:71-96 (2005)).
- Non-specific binding sites are blocked with non-target protein preparations and detergents.
- the capture antibody is then incubated with a preparation of urine or tissue containing the BTM antigen.
- the mixture is washed before the antibody/antigen complex is incubated with a second antibody that detects the target BTM.
- the second antibody is typically conjugated to a fluorescent molecule or other reporter molecule that can either be detected in an enzymatic reaction or with a third antibody conjugated to a reporter (Crowther, Id.).
- the preparation containing the BTM can be bound to the support or bead and the target antigen detected directly with an antibody-reporter conjugate (Crowther, Id.).
- the methods can also be used for immunodetection of marker family members in sera or plasma from bladder cancer patients taken before and after surgery to remove the tumour, immunodetection of marker family members in patients with other cancers, including but not limited to, colorectal, pancreatic, ovarian, melanoma, liver, oesophageal, stomach, endometrial, and brain and immunodetection of marker family members in urine and stool from bladder cancer patients.
- BTMs can also be detected in tissues or urine using other standard immunodetection techniques such as immunoblotting or immunoprecipitation (Harlow, E. and Lane, D., Using antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (1999)).
- immunoblotting protein preparations from tissue or fluid containing the BTM are electrophoresed through polyacrylamide gels under denaturing or non-denaturing conditions. The proteins are then transferred to a membrane support such as nylon. The BTM is then reacted directly or indirectly with monoclonal or polyclonal antibodies as described for immunohistochemistry. Alternatively, in some preparations, the proteins can be spotted directly onto membranes without prior electrophoretic separation. Signal can be quantified by densitometry.
- a soluble preparation containing the BTM is incubated with a monoclonal or polyclonal antibody against the BTM.
- the reaction is then incubated with inert beads made of agarose or polyacrylamide with covalently attached protein A or protein G.
- the protein A or G beads specifically interact with the antibodies forming an immobilized complex of antibody-BTM-antigen bound to the bead. Following washing the bound BTM can be detected and quantified by immunoblotting or ELISA.
- thresholds will be derived that will enable a sample to be called either positive or negative for TCC. These thresholds will be determined by the analysis of cohorts of patients who are being investigated for the presence of TCC. Thresholds may vary for different test applications; for example, thresholds for use of the test in population screening will be determined using cohorts of patients who are largely free of urological symptoms, and these thresholds may be different to those used in tests for patients who are under surveillance for TCC recurrence, or those being investigated for the presence of urological symptoms such as hematuria.
- a threshold could be selected to provide a practical level of test specificity in the required clinical setting; that is, a specificity that allows reasonable sensitivity without excessive numbers of patients receiving false positive results. This specificity may be within the range of 80-90%.
- An alternative method to obtain a test threshold is to plot sensitivity against specificity for different test thresholds (ROC curves) then select the point of inflexion of the curve.
- the test may use test intervals which provide different degrees of likelihood of presence of disease and which have different clinical consequences associated with them. For example, a test may have three intervals; one associated with a high (eg 90%) risk of the presence of TCC, a second associated with a low risk of TCC and a third regarded as being suspicious of disease.
- the “suspicious” interval could be associated with a recommendation for a repeat test in a defined period of time.
- assays for BTM can be desirably carried out on urine samples.
- methods for assaying for oligonucleotides, proteins and peptides in these fluids are known in the art.
- urine levels of a BTM can be quantified using a sandwich-type enzyme-linked immunosorbent assay (ELISA).
- ELISA enzyme-linked immunosorbent assay
- a 5 ⁇ L aliquot of a properly diluted sample or serially diluted standard BTM and 75 ⁇ L of peroxidase-conjugated anti-human BTM antibody are added to wells of a microtiter plate.
- anti-BTM antibodies can be monoclonal antibodies or polyclonal antisera.
- diagnosis of bladder cancer can be determined by measuring either expression of BTMs in a sample, or accumulation of BTMs in a sample.
- Prior art methods of diagnosis include cystoscopy, cytology and examination of cells extracted during these procedures. Such methods have relied upon identification of tumour cells in the urine or in a brush sample of urothelium, or in other cases, in biopsy specimens of the bladder wall. These methods suffer from several types of errors, including sampling error, errors in identification between observers, and the like.
- this invention includes manufacture of antibodies against BTMs.
- novel BTMs can be identified using microarray and/or qPCR methods. Once a putative marker is identified, it can be produced in sufficient amount to be suitable for eliciting an immunological response. In some cases, a full-length BTM can be used, and in others, a peptide fragment of a BTM may be sufficient as an immunogen.
- the immunogen can be injected into a suitable host (e.g., mouse, rabbit, etc) and if desired, an adjuvant, such as Freund's complete adjuvant, Freund's incomplete adjuvant can be injected to increase the immune response. It can be appreciated that making antibodies is routine in the immunological arts and need not be described herein further. As a result, one can produce antibodies against BTMs identified using methods described herein.
- antibodies can be made against the protein or the protein core of the tumour markers identified herein or against an oligonucleotide sequence unique to a BTM.
- BTM immunogens can include deglycosylated BTM or deglycosylated BTM fragments. Deglycosylation can be accomplished using one or more glycosidases known in the art.
- BTM cDNA can be expressed in glycosylation-deficient cell lines, such as prokaryotic cell lines, including E. coli and the like.
- Vectors can be made having BTM-encoding oligonucleotides therein. Many such vectors can be based on standard vectors known in the art. Vectors can be used to transfect a variety of cell lines to produce BTM-producing cell lines, which can be used to produce desired quantities of BTM for development of specific antibodies or other reagents for detection of BTMs or for standardizing developed assays for BTMs.
- kits can be made that have a detection device pre-loaded with a detection molecule (or “capture reagent”).
- a detection device pre-loaded with a detection molecule (or “capture reagent”).
- such devices can comprise a substrate (e.g., glass, silicon, quartz, metal, etc) on which oligonucleotides as capture reagents that hybridize with the mRNA to be detected is bound.
- direct detection of mRNA can be accomplished by hybridizing mRNA (labeled with cy3, cy5, radiolabel or other label) to the oligonucleotides on the substrate.
- detection of mRNA can be accomplished by first making complementary DNA (cDNA) to the desired mRNA. Then, labeled cDNA can be hybridized to the oligonucleotides on the substrate and detected.
- cDNA complementary DNA
- Antibodies can also be used in kits as capture reagents.
- a substrate e.g., a multiwell plate
- a specific BTM capture reagent attached thereto.
- a kit can have a blocking reagent included. Blocking reagents can be used to reduce non-specific binding. For example, non-specific oligonucleotide binding can be reduced using excess DNA from any convenient source that does not contain BTM oligonucleotides, such as salmon sperm DNA.
- Non-specific antibody binding can be reduced using an excess of a blocking protein such as serum albumin
- a blocking protein such as serum albumin
- a test kit can comprise capture reagents (such as probes), washing solutions (e.g., SSC, other salts, buffers, detergents and the like), as well as detection moieties (e.g., cy3, cy5, radiolabels, and the like). Kits can also include instructions for use and a package.
- capture reagents such as probes
- washing solutions e.g., SSC, other salts, buffers, detergents and the like
- detection moieties e.g., cy3, cy5, radiolabels, and the like.
- Kits can also include instructions for use and a package.
- reagents for the testing the BTM LTBDH4 in combination with over-expressing BTMs can be incorporated into a kit for the testing of unfractionated urine or urine cell sediments to detect bladder cancer.
- the urine samples could be collected from patients with diagnosed bladder cancer who require monitoring for disease progression or treatment response, individuals with urological symptoms including macroscopic or microscopic hematuria, or asymptomatic individuals.
- a kit that measures the BTMs in unfractionated urine approximately 2 mls of urine can be taken for testing.
- >10 mls of urine can be collected.
- a suitable kit includes: (i) instructions for use and result interpretation, (ii) software for interpretation of multiple gene analyses, including any regression analysis classifier or formula (iii) reagents for the stabilization and purification of RNA from unfractionated urine or urine pellets, (iv) reagents for the synthesis of cDNA including dNTPs and reverse transcriptase, and (v) reagents for the quantification of the BTM cDNA.
- these reagents would be used for quantitative PCR and would include specific exon-spanning oligonucleotide primers, a third oligonucleotide labeled with a probe for detection, Taq polymerase and the other buffers, salts and dNTPs required for PCR.
- the kit can also use other methods for detection of the transcripts such as direct hybridization of the BTM RNA with labeled probes or branched DNA technology; and (vi) oligonucleotides and probe for the detection of transcripts from a highly transcribed gene, such as ⁇ -actin, to serve as a quality control measure.
- samples of tissue are obtained by biopsy of bladder wall or samples of urine are collected over time from a patient having bladder cancer. Evaluation of the ratio of BTMs or combinations thereof are made for samples taken at different times. BTM ratios within a specified range are indicative of progression of bladder cancer.
- samples of tissue and/or urine are obtained before treatment is initiated.
- the baseline levels of one or more BTMs are determined, as are ratios of various BTMs with respect to each other.
- Treatment is initiated, and can include any therapy known in the art, including surgery, radiation therapy or chemotherapy as appropriate to the type and stage of the disease.
- samples of tissue and/or urine are collected and analyzed for the presence and amount of BTMs. Ratios of various BTMs are determined and results are compared to: (1) the patient's baseline levels before treatment or (2) normal values obtained from a population of individuals not having bladder cancer.
- BTM marker ratios detected in either tissue, serum or urine can be used to monitor a patient's response to therapy.
- urine and/or serum samples can be taken at intervals following the initiation of systemic, intravesicular or intravascular chemotherapy, radiotherapy or immunotherapy.
- a change in marker ratio can indicate a reduction in tumour size, indicative of effective treatment. The rate of change can be used to predict the optimum therapeutic dose for each patient or treatment.
- regression or classification analyses that include high and low expressing BTM family members can be used for the applications described above.
- Markers evaluated are selected from known human genes.
- the genes evaluated are indicated in FIGS. 3 and 4 . Included in FIGS. 3 and 4 are the name of the gene, the HUGO identifier, MWG oligo number, NCBI mRNA reference sequence number and the protein reference number. The full length sequences can be found at http_:_//_www_._ncbi_._nlm_._nih_._gov_/_entrez/.
- Bladder tumour samples and non-malignant urothelium samples were collected from surgical specimens resected at Kyoto University Hospital, Japan.
- Urine samples from non-malignant controls and bladder cancer patients were obtained from Kyoto University Hospital, Japan. Healthy control samples were obtained from Japanese volunteers ( FIG. 1 ).
- RNA was extracted from urine by mixing the urine sample with an equal volume of lysis buffer (5.64M guanidine-HCl, 0.5% sarkosyl, 50 mM sodium acetate (pH 6.5) and 1 mM ⁇ -mercaptoethanol; pH adjusted to 7.0 with 1.5M Hepes pH 8). Due to the low amounts of RNA in urine, 7.5 ugs of total bacterial RNA was added to the urine/lysis buffer mix to act as a carrier. Total RNA was then extracted using Trizol and the RNeasyTM procedure. RNA preparations were further purified prior to cDNA synthesis using the Qiagen QIAquickTM PCR purification kit.
- Epoxy coated glass slides (MWG Biotech) were printed with ⁇ 30,000 50mer oligonucleotides (MWG Biotech) using a Gene Machines microarraying robot, according to the manufacturer's protocol.
- cDNA was transcribed from 5 ⁇ g total RNA using Superscript IITM reverse transcriptase (Invitrogen) in reactions containing 5-(3-aminoallyl)-2′ deoxyuridine-5′-triphosphate. The reaction was then de-ionised in a Microcon column before being incubated with Cy3 or Cy5 in bicarbonate buffer for 1 hour at room temperature. Unincorporated dyes were removed using a Qiaquick column (Qiagen) and the sample concentrated to 15 ⁇ l in a SpeedVac. Cy3 and Cy5 labeled cDNAs were then mixed with Ambion ULTRAhybTM buffer, denatured at 100° C. for 2 min and hybridized to the microarray slides in hybridisation chambers at 42° C. for 16 hours. The slides were then washed and scanned twice in an Axon 4000ATM scanner at two power settings.
- Superscript IITM reverse transcriptase Invitrogen
- RNA from 53 bladder tumours and 20 non-malignant (“normal”) bladder tissue samples were labeled with Cy5 and hybridized in duplicate or triplicate with Cy3 labeled reference RNA. After normalization, the change in expression in each of 29,718 genes was then estimated by fold change and statistical probability.
- Total urine RNA was annealed to gene-specific primers for each of the bladder tumour markers by incubating at 70° C. then cooling on ice for 2 mins in 50 ⁇ l reactions containing forward primers at 0.01 ⁇ g/ ⁇ l.
- Each cDNA reaction contained annealed RNA and 4 ⁇ l of 5 ⁇ Superscript II reverse transcriptase buffer (Invitrogen, USA), 2 ⁇ l of 0.1M DTT (Invitrogen, USA), 0.5 ⁇ l of RNase out (40U/ ⁇ L), (Invitrogen, USA), 4 ⁇ l of 10 mM dNTP (Invitrogen, USA) and 0.5 ⁇ l of Superscript II reverse transcriptase (200U/ ⁇ l), (Invitrogen, USA) in a final volume of 20 ⁇ l.
- Reactions were incubated at 42° C. for 1 hour, 10 minutes at 70° C. and 1 minute at 80° C. Reactions were cleaned prior to qPCR with Qiagen QIAquick PCR purification columns (Qiagen, Victoria, Australia) and stored at ⁇ 80° C.
- qPCR Real-time or quantitative PCR
- TaqmanTM probe and primer sets were designed using Primer Express V 2.0TM (Applied Biosystems). Where possible, all potential splice variants were included in the resulting amplicon, with amplicon preference given to regions covered by the MWG-Biotech-derived microarray oligonucleotide. Primer and probe sequences are shown in FIG. 2 . Alternatively, if the target gene was represented by an Assay-on-DemandTM expression assay (Applied Biosystems) covering the desired amplicons, these were used.
- primer concentration was titrated using a SYBR green labeling protocol and cDNA made from the reference RNA Amplification was carried out on an ABI PrismTM 7000 sequence detection system under standard cycling conditions.
- standard curves were generated over a 625 fold concentration range using optimal primer concentrations and 5′FAM-3′TAMRA phosphate TaqmanTM probe (Proligo) at a final concentration of 250 nM.
- Assays giving standard curves with regression coefficients over 0.98 were used in subsequent analyses.
- Assays were performed in 96 well plates. Each plate contained a reference cDNA standard curve, over a 625-fold concentration range.
- total RNA extracted from ⁇ 0.5 mls unfractionated urine was used in each reaction.
- the ⁇ Ct (target gene Ct—mean reference cDNA Ct) was calculated for each marker, and used in subsequent ratios, regression or classification analysis.
- FIGS. 3 and 4 The expression of the markers shown in FIGS. 3 and 4 in whole blood was determined in silico. Microarray probes were linked to UniGene clusters via the GenBank accession numbers of their target mRNAs, and the tissue expression profile from UniGene used to determine the number of expressed sequence tags (ESTs) in blood libraries. Only genes with 0 or 1 expressed sequence tags (EST) are shown in FIG. 4 . To confirm the low expression of LTB4DH in whole blood, RT-qPCR was carried out on total RNA extracted from whole blood using the primers and probes shown in FIG. 2 . No significant expression was observed (results not shown).
- FIG. 3 shows the statistical analysis of microarray data for 300 genes that show significant downregulation in bladder cancer tissue compared to non-malignant tissue.
- FIG. 3 includes the HUGO gene name and symbol, the protein reference sequence number, the NCBI mRNA reference sequence number, the MWG Biotech probe oligonucleotide number, the median fold change in gene expression between tumour and non-malignant tissue, the results of an original unadjusted Student's t-test, the results of the 2-sample Wilcoxon test, the results of the SAM test, and the summated rank score.
- bladder cancer markers are not significantly elevated in whole blood.
- the downregulated markers are being used in ratios, regression or classification analysis, it is an advantage that they be present in sufficiently high copy numbers in both tumour cells and non-malignant bladder cells to enable reliable detection in urine.
- To identify suitable markers we screened the genes in FIG. 3 for a subset that had little or no representation in blood EST libraries, and had higher than median expression in non-malignant tissue. Median expression was estimated by ranking the 30,000 oligonucleotides on the array by their median intensity in the samples analysed in the microarray study. Markers that met the criteria are shown in FIG. 4 .
- the HUGO gene name and symbol includes the HUGO gene name and symbol, the protein reference sequence number, the NCBI mRNA reference sequence number, the median fold change, the rank score, the median rank of microarray spot intensity in tumour tissue and non-malignant tissue, and the number of ESTs present in blood EST libraries.
- LTB4DH LTB4DH
- BAG1 BAG1
- FLJ21511 The down regulation observed in the array data was validated by qPCR for three genes shown in FIG. 4 , LTB4DH, BAG1 and FLJ21511. These genes were tested on total RNA from 10 tumour samples and 10 non-malignant samples. LTB4DH, BAG1 and FLJ21511 showed an average downregulation in bladder tumours compared to bladder non-malignant tissue of 2.5 fold, 1.4 fold and 6.1 fold, respectively, in these samples.
- Urine from TCC patients and controls with non-malignant urological conditions was collected by either voiding or catheterisation.
- Total RNA was extracted from the voided urine of 42 controls and the voided or catheterised urine of 37 TCC patients and used in quantitative RT-PCR using primers and probes for LTB4DH and three over-expressed markers, IGFBP5, MDK and HoxA13.
- the ⁇ Ct ratios were determined for IGFBP5/LTB4DH, MDK/LTB4DH and HoxA13/LTB4DH. This data is illustrated by the box plots in FIG. 5 , which show a clear difference in the spread of data between the urine samples from controls and TCC patients for each of the three tests.
- IGFBP5/LTB4DH which demonstrated sensitivity and specificity of 87% and 88% in this sample cohort, respectively ( FIG. 6 a ).
- ROC curves are shown in FIGS. 7A-7C .
- the areas under the curve for IGFBP5/LTB4DH, MDK/LTB4DH and HoxA13/LTB4DH are 0.9223, 0.9199, and 0.7497, respectively. These areas, which measure test accuracy, indicate that all three ratios with LTB4DH are useful tests, in particular IGFBP5/LTB4DH and MDK/LTB4DH.
- FIGS. 8A-8F shows the separation of data in 2 dimensional space for each of the three tests using LTB4DH and BAG1. This data shows that combinations of two or more tests that include either of the downregulated BTMs LTB4DH or BAG1, are able to achieve sensitivities and specificities of over 90%. Moreover, because these tests are measuring simple gene expression signatures and not absolute levels of markers, they will be robust to variations in urine concentration.
- the method of urine sample collection can affect the amount of marker detected due to variations in the number of exfoliated bladder cells collected. This bias could lead to false positive or false negative results in a small proportion of samples.
- ratios including LTB4DH or other low-expressing genes should provide a method to compensate for different methods.
- samples collected from TCC patients by either simple voiding (nine samples) or catheterisation (28 samples) were tested for the presence of TCC markers and LTB4DH. Analysis of the TCC markers alone showed that the voided samples were more heavily represented at the lower end of the range of data (higher Ct), consistent with a lower average number of exfoliated cells in these samples compared to the catheterised samples.
- Urine samples from patients with low grade tumours are often borderline in their accumulation of BTMs due to the presence of only small numbers of exfoliated cells in these samples. These samples are therefore at high risk of being incorrectly classified due to variations in sampling method or urine concentration.
- LTB4DH increased the accuracy of detection of low grade (grade 1-2) stage Ta TCCs by 9% and low grade TCCs of any stage by 8%.
- the accuracy of HoXA13 testing of low grade stage Ta TCCs was increased by 3%.
- Linear discriminate analysis is a statistical technique (Fisher R. A. “The Use of Multiple Measurements in Taxonomic Problems”, Annals of Eugenics 7 179 (1936)) in which a linear combination of variables is generated, such that there is maximal separation between two or more groups. This linear combination of variables is termed the “linear discriminant”, which is a linear function of the input variables that maximally separates the classes of the data set.
- LDA Linear discriminate analysis
- the partitioning of the dataset into training and testing sets can be repeated multiple times (each time generating a new classifier).
- k-fold cross-validation the dataset is split k-wise, and each subset is used as the testing set in one of k rounds of training and validation. This can be extended to leave-one-out cross-validation (LOOCV) where each sample is classified according to a classifier generated from the remaining samples in the dataset (“leaving one out”; leaving out the sample which is being tested).
- LOOCV leave-one-out cross-validation
- LDA and LOOCV were used to illustrate the utility of the downregulated BTM, LTB4DH, in improving the diagnosis of TCC.
- Combinations of the six genes LTB4DH, MDK, IGFBP5, HOXA13, TOP2a and CDC2 were tested for classifier performance, as judged by LOOCV.
- the posterior probability (that the sample “left out” was a TCC sample) was used to generate ROC curves using the ROCR package of the R statistical programming environment.
- the sensitivity of the classifier for a given specificity was obtained by reference to the appropriate ROC curve.
- the sensitivity of detection of TCC using combinations of upregulated BTMs with and without LTB4DH was determined at a specificity of 85%.
- the results of this analysis are shown in FIG. 15 . It can be seen that the addition of LTB4DH to assays including combinations of the upregulated BTMs MDK, IGFBP5, Top2a, cdc2 and HoxA13 increased the overall sensitivity by 1-2% and the sensitivity of detection of Stage Ta tumours, grade 1-2 tumours and grade 3 tumours by up to 3%.
- Methods for detecting BTM family members include detection of nucleic acids, proteins and peptides using microarray and/or real time PCR methods.
- the compositions and methods of this invention are useful in diagnosis of disease, evaluating efficacy of therapy, and for producing reagents and test kits suitable for measuring expression of BTM family members.
Abstract
Description
- This application is a Continuation of U.S. patent application Ser. No. 14/902,552 (now U.S. Pat. No. 9,809,860, issued 7 Nov. 2017), which is a Division of U.S. application Ser. No. 12/843,435 entitled “Urine Gene Expression Ratios for Detection of Cancer,” which is a continuation application filed under 35 U.S.C. § 1.111(a) and 37 C.F.R. § 1.53(b) of U.S. application Ser. No. 12/221,626, filed 5 Aug. 2008, which claims priority to PCT International Application Number PCT/NZ2007/000029,
International Filing Date 16 Aug. 2007, Inventor Parry Guilford, entitled “Urine Gene Expression Ratios for Detection of Cancer.” The above PCT Application claims priority to New Zealand provisional patent application number NZ 545,243, filed 10 Feb. 2006. Each of the above applications and patent is expressly incorporated herein fully by reference, as if individually so incorporated. - This invention relates to detection of cancer. Specifically, the invention relates to the use of markers for the detection of bladder cancer. More specifically, this invention relates to use of an under-expressed marker in combination with at least one other marker for the detection of bladder cancer.
- Survival of cancer patients is greatly enhanced when the cancer is treated early. In the case of bladder cancer, patients diagnosed with early stage disease have 5-year survival rates of >90%, compared to approximately 15-30% for patients diagnosed with advanced disease. Therefore, developments that lead to early diagnosis of bladder cancer can lead to an improved prognosis for the patients. The established method for detecting bladder cancer using urine samples is cytology. However, cytology is known to be only about 75% sensitive for detecting invasive bladder cancer and only about 25% sensitive for detecting superficial bladder cancer (Lotan and Roehrborn, Urology 61, 109-118 (2003)).
- Identification of specific markers for cancer in urine can provide a valuable approach for the early diagnosis of cancer, leading to early treatment and improved prognosis. Specific cancer markers also provide a means for monitoring disease progression, enabling the efficacy of surgical, radiotherapeutic and chemotherapeutic treatments to be monitored.
- At present, the most reliable method for detecting bladder cancer is cystoscopy accompanied by histology of biopsied lesions. However, this technique is time consuming, invasive and its sensitivity is only approximately 90%, meaning that about 10 percent of cancers are not detected using these methods. Of the non-invasive methodologies, urine cytology, which detects exfoliated malignant cells microscopically, is the current preferred method. Although cytology has a specificity of about 95%, it has poor sensitivity (9-25%) for low-grade lesions, is extremely dependent on sample quality and suffers from high inter-observer variability.
- Several urine protein markers are known. Tests for these markers offer better sensitivity than cytology, but tend to suffer from sub-optimal specificity because elevated levels of these markers are also commonly observed in patients with non-malignant diseases including inflammation, urolithiasis and benign prostatic hyperplasia. For example, NMP22, which detects a specific nuclear matrix protein, has a sensitivity of 47-87% and a specificity of 58-91%.
- One drawback associated with urine testing is that individual marker levels can vary significantly with: (i) different urine collection methods (catheterised, voided, urine pellets); (ii) the diurnal timing of urine sampling; (iii) the point of sampling during voiding (e.g. midstream vs end sample); and (iv) urine concentration associated with varying fluid intake, kidney function or diseases that affect plasma volume. These variations have the potential to lead to false positive and false negative tests. Although some of this variation can be reduced using strict standard operating procedures, patient compliance with these procedures can be unreliable. The effect of varying urine concentration can, in some instances, be accounted for by assessing marker levels relative to urinary creatinine, however, this increases the cost and complexity of testing, particularly when sample preparation or storage methods differ for marker detection and creatinine measurement.
- There is a need for simple tools for the early detection and diagnosis of cancer. This invention provides further methods, devices and kits based on markers, specifically ratios, regression or classification analysis of bladder cancer markers, to aid in the detection and diagnosis of bladder cancer.
- The present invention provides for a method for determining the presence of a cancer in a subject, comprising:
- (a) providing a sample from the subject;
- (b) detecting the expression level of at least two tumour marker (TM) family members in said sample, wherein at least one TM is an under-expressed TM;
- (c) establishing whether the patient has cancer according to a predetermined threshold.
- Step (c) can be preformed by determining the ratio of expression of said TMs, or by performing regression or classification analysis on the TM expression levels.
- The TM can be a BTM. The cancer to be detected can be bladder cancer, and in certain embodiments at least one of the TMs is an over-expressed BTM. The over-expressed BTM may be selected from the group outlined in
FIG. 11 orFIG. 12 . - In certain embodiments at least one under-expressed TM is a BTM selected from the group outlined in
FIG. 3 orFIG. 4 . - In other embodiments of the present invention the step of detecting is carried out by detecting over expression of BTM mRNA, a BTM protein, or a BTM peptide.
- The sample can be any one of biopsy, blood, serum, peritoneal washes, cerebrospinal fluid, urine and stool samples
- The present invention also provides for a device for detecting a TM, comprising:
- a substrate having a TM capture reagent thereon; and
- a detector associated with said substrate, said detector capable of detecting a TM associated with said capture reagent, wherein the TM is an under-expressed TM.
- The TM can be a BTM.
- The TM capture reagent can be an oligonucleotide or an antibody.
- In certain embodiments the TM can be a BTM selected from the group outlined in
FIG. 3 orFIG. 4 . - The present invention also provides for a kit for determining the presence of a cancer in a subject, comprising:
- a substrate;
- at least two TM capture reagents, wherein at least one TM is an under-expressed TM; and
- instructions for use.
- The TM can be a BTM.
- The TM capture reagent may be a TM-specific oligonucleotide or a TM-specific antibody.
- The TM detected by the kit may be a BTM selected from the group outlined in
FIG. 3 orFIG. 4 . - At least one of the TMs detected by the kit may be an over-expressed TM or an over-expressed BTM. The over-expressed BTM may be selected from the group outlined in
FIG. 11 orFIG. 12 . - This invention is described with reference to specific embodiments thereof and with reference to the Figures, in which:
-
FIG. 1 depicts a table showing the characteristics of urine samples used in the qPCR analyses. -
FIG. 2 depicts a table of primers and oligonucleotide probes of markers for qPCR analysis of bladder cancer according to the present invention. -
FIG. 3 depicts a table of under-expressing bladder tumour markers identified using microarray methods on samples of bladder cancer. -
FIG. 4 depicts a table of under-expressing bladder tumour markers identified using microarray methods on samples of bladder cancer that have insignificant expression in whole blood, but high expression in normal bladder tissue. -
FIG. 5 depicts box and whisker plots showing the ratios of three bladder transitional cell carcinoma (TCC) markers (HoxA13, IGFBP5, and MDK) with the under expressing marker LTB4DH for urine samples from patients with either non-malignant urological disease or TCC. The boxes define the 25th, 50th and 75th percentiles and the horizontal bars mark the adjacent values. Outliers are shown by circles. The unfilled boxes represent samples from non-malignant disease controls and the shaded boxes represent samples from patients with TCC. -
FIGS. 6A-6B show examples of the sensitivities and specificities of TCC detection for tests that include LTB4DH. -
FIG. 6A . single tests; -
FIG. 6B . combination tests using LTB4DH and two of the three markers HoxA13, IGFBP5, and MDK. -
FIGS. 7A-7C show ROC curves for the sensitivity and specificity of detection of TCC in urine samples using ratios that include LTB4DH. -
FIG. 7A . IGFBP5/LTB4DH; -
FIG. 7B . MDK/LT4BDH; -
FIG. 7C . HoxA13/LTB4DH. -
FIGS. 8A-8F show scatter plots for combination tests,FIGS. 8A-C using LTB4DH and two of the three markers HoxA13, IGFBP5, and MDK, andFIGS. 8D-F repeated using BAG1 for LTB4DH. -
FIG. 8A . MDK/LTB4DH and IGFBP5/LTB4DH; -
FIG. 8B . MDK/LTB4DH and HoxA13/LTB4DH; -
FIG. 8C . IGFBP5/LTB4DH and HoxA13/LTB4DH; -
FIG. 8D MDK/BAG1 and IGFBP5/BAG1; -
FIG. 8E . MDK/BAG1 and HoxA13/BAG1; -
FIG. 8F . IGFBP5/BAG1 and HoxA13/BAG1. -
FIGS. 9A-9B show scatter plots showing the correlation between ΔCt for IGFBP5 and ΔCt ratios for IGFBP5/LTB4DH and urine creatinine concentration. -
FIG. 9A . Urine samples from patients with TCC -
FIG. 9B . Urine samples from patients with non-malignant disease -
FIGS. 10A-10F depict self-self scatter plots showing the distribution of voided and catheterised urine samples from TCC patients analysed using the bladder tumour markers MDK, IGFBP5 and HoxA13 alone or in ratios with LTB4DH. -
FIG. 10A depicts a self-self scatter plot for MDK. -
FIG. 10B depicts a self-self scatter plot for MDK/LTB4DH. -
FIG. 10C depicts a self-self scatter plot for IGFBP5. -
FIG. 10D depicts a self-self scatter plot for IGFB5/LTB4DH. -
FIG. 10E depicts a self-self scatter plot for HoxA13. -
FIG. 10F depicts a self-self scatter plot for HoxA13/LTB4DH -
FIG. 11 shows known over-expressed markers from invasive bladder tumours. -
FIG. 12 shows known over-expressed markers from superficial bladder tumours. -
FIG. 13 shows the clinical characteristics of low grade TCC samples and controls used in ROC curve analysis. -
FIG. 14 shows the results of a ROC Curve analysis. Illustration of the increased test accuracy obtained when LTB4DH is used in ratios with HoxA13 and IGFBP5. -
FIG. 15 shows the results of a Linear Discriminate Analysis of BTMs, with and without LTB4DH, for the detection of TCC. - The term “marker” means a molecule that is associated quantitatively or qualitatively with the presence of a biological phenomenon. Examples of “markers” include a polynucleotide, such as a gene, gene fragment, RNA, or RNA fragment; or a gene product, including a polypeptide such as a peptide, oligopeptide protein or protein fragment; or related metabolites, by products or other identifying molecules, such as antibodies or antibody fragments whether related directly or indirectly to a mechanism underlying the phenomenon. The markers of the invention include the nucleotide sequences (e.g. GenBank sequences) as disclosed herein, in particular the full length sequences, any coding sequences, non-coding sequences and fragments, or any compliments thereof, and any measurable marker thereof as defined above.
- The term “sensitivity” means the proportion of individuals with the disease who test (by the model) positive. Thus, increased sensitivity means fewer false negative test results.
- The term “specificity” means the proportion of individuals without the disease who test (by the model) negative. Thus, increased specificity means fewer false positive test results.
- The term “expression” includes production of polynucleotides and polypeptides, in particular, the production of RNA (e.g., mRNA) from a gene or portion of a gene, and includes the production of a polypeptide encoded by an RNA or gene or portion of a gene, and includes appearance of a detectable material associated with expression. For example, the formation of a complex, for example, from a polypeptide-polypeptide interaction, polypeptide-nucleotide interaction, or the like, is included within the scope of the term “expression”. Another example, the binding of a binding ligand, such as a hybridization probe or antibody, to a gene or other polynucleotide, a polypeptide or a protein fragment and the visualization of the binding ligand Thus, the density of a spot on a microarray, on a hybridization blot such as a Northern blot, or on an immunoblot, such as a Western blot, or on a bead array, or by PCR analysis, is included within the term “expression” of the underlying biological molecule.
- The term “over expression” is used where the expression of a marker in one cell, or cell type, is greater than that of another equivalent cell, or cell type.
- The term “under expression” is used where the expression of a marker in one cell, or cell type, is less than that of another equivalent cell, or cell type.
- The term “TM” or “tumour marker” or “TM family member” means a marker that is associated with a particular cancer. The term TM also includes combinations of individual markers, whose combination improves the sensitivity and specificity of detecting cancer. It is to be understood that the term TM does not require that the marker be specific only for a particular tumour. Rather, expression of TM can be altered in other types of cells, diseased cells, tumours, including malignant tumours.
- A TM can be identified by extracting RNA from a tissue sample from a patient suspected of having bladder cancer, applying the RNA or cDNA copy to a microarray having a number of oligonucleotides thereon, permitting the sample RNA to hybridize to the oligonucleotides on the array, and then quantifying the level of measured RNA bound to the each array spot. A marker is considered to be a under expressing TM if its presence is below a threshold of at least about 1.2 times that found in normal, non-malignant tissue using microarray methods. Alternatively, the threshold can be below about 2 times normal, about 3 times less than normal, 4 times or even about 5 times less than normal. By “normal” we mean less than the 90th percentile of the normal population. In other cases, normal can mean a level of presence of the 95th percentile (i.e., about 2 Standard Deviations (SD) from the mean), and in other cases, less than about 97.5th percentile (i.e., about 3 SD) or the 99th percentile.
- The term “under expressing TM” means a marker that shows lower expression in bladder tumours than in non-malignant bladder tissue. The term “over expressing TM” means a marker that shows higher expression in bladder tumours than in non-malignant tissue.
- The term “BTM” or “bladder tumour marker” or “BTM family member” means a TM that is associated with bladder cancer. The term BTM also includes combinations of individual markers, whose combination improves the sensitivity and specificity of detecting bladder cancer. It is to be understood that the term BTM does not require that the marker be specific only for bladder tumours. Rather, expression of BTM can be altered in other types of cells, diseased cells, tumours, including malignant tumours.
- The term “under expressing BTM” means a marker that shows lower expression in bladder tumours than in non-malignant bladder tissue.
- The term “over expressing BTM” means a marker that shows higher expression in bladder tumours than in non-malignant tissue.
- The term “qPCR” means quantitative polymerase chain reaction. The term “qPCR” or “QPCR” refers to quantitative polymerase chain reaction as described, for example, in PCR Technique: Quantitative PCR, J. W. Larrick, ed., Eaton Publishing, 1997, and A-Z of Quantitative PCR, S. Bustin, ed., IUL Press, 2004.
- The term “TCC” means transitional cell carcinoma of the bladder. TCCs constitute ˜95% of all bladder cancers.
- As used herein “antibodies” and like terms refer to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. These include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fc, Fab, Fab′, and Fab2 fragments, and a Fab expression library. Antibody molecules relate to any of the classes IgG, IgM, IgA, IgE, and IgD, which differ from one another by the nature of heavy chain present in the molecule. These include subclasses as well, such as IgG1, IgG2, and others. The light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all classes, subclasses, and types. Also included are chimeric antibodies, for example, monoclonal antibodies or fragments thereof that are specific to more than one source, e.g., a mouse or human sequence. Further included are camelid antibodies, shark antibodies or nanobodies.
- The terms “cancer” and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by abnormal or unregulated cell growth. Cancer and cancer pathology can be associated, for example, with metastasis, interference with the normal functioning of neighbouring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, neoplasia, premalignancy, malignancy, invasion of surrounding or distant tissues or organs, such as lymph nodes, etc.
- The term “tumour” refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
- The term “microarray” refers to an ordered or unordered arrangement of capture agents, preferably polynucleotides (e.g., probes) or polypeptides on a substrate. See, e.g., Microarray Analysis, M. Schena, John Wiley & Sons, 2002; Microarray Biochip Technology, M. Schena, ed., Eaton Publishing, 2000; Guide to Analysis of DNA Microarray Data, S. Knudsen, John Wiley & Sons, 2004; and Protein Microarray Technology, D. Kambhampati, ed., John Wiley & Sons, 2004.
- The term “oligonucleotide” refers to a polynucleotide, typically a probe or primer, including, without limitation, single-stranded deoxyribonucleotides, single- or double-stranded ribonucleotides, RNA: DNA hybrids, and double-stranded DNAs. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are often synthesized by chemical methods, for example using automated oligonucleotide synthesizers that are commercially available, or by a variety of other methods, including in vitro expression systems, recombinant techniques, and expression in cells and organisms.
- The term “polynucleotide,” when used in the singular or plural, generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. This includes, without limitation, single- and double-stranded DNA, DNA including single- and double-stranded regions, single- and double-stranded RNA, and RNA including single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or include single- and double-stranded regions. Also included are triple-stranded regions comprising RNA or DNA or both RNA and DNA. Specifically included are mRNAs, cDNAs, and genomic DNAs, and any fragments thereof. The term includes DNAs and RNAs that contain one or more modified bases, such as tritiated bases, or unusual bases, such as inosine. The polynucleotides of the invention can encompass coding or non-coding sequences, or sense or antisense sequences. It will be understood that each reference to a “polynucleotide” or like term, herein, will include the full-length sequences as well as any fragments, derivatives, or variants thereof.
- “Polypeptide,” as used herein, refers to an oligopeptide, peptide, or protein sequence, or fragment thereof, and to naturally occurring, recombinant, synthetic, or semi-synthetic molecules. Where “polypeptide” is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, “polypeptide” and like terms, are not meant to limit the amino acid sequence to the complete, native amino acid sequence for the full-length molecule.
- It will be understood that each reference to a “polypeptide” or like term, herein, will include the full-length sequence, as well as any fragments, derivatives, or variants thereof.
- “Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridisable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. Additional details and explanation of stringency of hybridization reactions, are found e.g., in Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).
- “Stringent conditions” or “high stringency conditions”, as defined herein, typically: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ a denaturing agent during hybridization, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50% formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5×, Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodium citrate) and 50% formamide at 55° C., followed by a high-stringency wash comprising 0.1×SSC containing EDTA at 55° C.
- “Moderately stringent conditions” may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e. g., temperature, ionic strength, and % SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37° C. in a solution comprising: 20% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5× Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1×SSC at about 37-50° C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
- The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, such as, Molecular Cloning: A Laboratory Manual, 2nd edition, Sambrook et al., 1989; Oligonucleotide Synthesis, M J Gait, ed., 1984; Animal Cell Culture, R. I. Freshney, ed., 1987; Methods in Enzymology, Academic Press, Inc.; Handbook of Experimental Immunology, 4th edition, D. M. Weir & C C. Blackwell, eds., Blackwell Science Inc., 1987; Gene Transfer Vectors for Mammalian Cells, J. M. Miller & M. P. Calos, eds., 1987; Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., 1987; and PCR: The Polymerase Chain Reaction, Mullis et al., eds., 1994.
- Using a combination of microarray analysis and quantitative polymerase chain reaction (qPCR), markers for transitional cell carcinoma of the bladder (TCC) that are under-expressed in tumours have been identified. It has surprisingly been found that ratios between these markers and other bladder tumour markers (BTM), especially markers that are over expressed in tumours, are diagnostic for bladder cancer.
- The ratios (rather than measuring an absolute level of a marker) identifies a simple gene expression ‘signature’ that typifies bladder cancer cells, and surprisingly is more robust to variations in sampling techniques or urine concentration. Moreover, the combination of an under-expressed marker and an over-expressed marker maximizes the differential between samples from patients and non-malignant controls, increasing the test reliability. The under-expressed markers described here have been selected on the basis of (i) strong and consistent down-regulation in TCC, (ii) high expression in normal tissue, and (iii) insignificant expression in whole blood to minimize the risk of false positives in patients presenting with hematuria.
- As an alternative to determining the ration of the two BTMs it has also been found that the under-expressed and over-expressed BTMs can be analysed in regression analyses or classification techniques including linear discriminate analysis, and the results of these analyses are also indicative of the presence of bladder cancer.
- The test involves the measuring of at least two TM markers, such as a BTM, in a sample from a patient suspected of having a cancer or at risk of having cancer, wherein at least one of the TMs is an under-expressed TM. The ratio of the under-expressed TM and the other TM is indicative of the presence of cancer. The second TM can be any TM as known in the art, but preferably is an over-expressed BTM.
FIG. 3 shows a number of under-expressed markers suitable for use in the present invention. - The test is best preformed using an under-expressed TM in combination with an over-expressed TM. Any over-expressed TM can be used, for example. Known over expressed BTMs identified from invasive bladder tumours (defined here as tumours ≥stage 1), are outlined in
FIG. 11 , and over-expressed BTMs identified from superficial bladder tumours (defined here as Stage Ta and Tis tumours) are shown inFIG. 12 . - It has also been surprisingly established that preferred under-expressed BTMs for use in the present invention are ones that are not significantly elevated in whole blood, and are present in sufficiently high copy numbers in both tumour cells and non-malignant bladder cells. Preferred under-expressed BTMs are outlined in
FIG. 4 . - Cancer markers can be detected in a sample using any suitable technique, and can include, but are not limited to, oligonucleotide probes, qPCR or antibodies raised against cancer markers.
- It will be appreciated that the sample to be tested is not restricted to a sample of the tissue suspected of being a tumour. The marker may be secreted into the serum, sloughed from cell membranes, released from lysed cells or associated with cells lost into the urine. Therefore, a sample can include any bodily sample, and includes biopsies, blood, serum, peritoneal washes, cerebrospinal fluid, urine and stool samples.
- It will also be appreciate that the present invention is not restricted to the detection of cancer in humans, but is suitable for the detection of cancer in any animal, including, but not limited to dogs, cats, horses, cattle, sheep, deer, pigs and any other animal known to get cancer.
- The following approaches are non-limiting methods that can be used to measure TMs. Following measurement of individual TMs, ratios between high and low expressing BTM family members are determined. These ratios are used to predict the presence or absence cancer.
- Alternatively, the high and low expressing TMs are used in regression or classification analyses. The results of these analyses are also used to predict the presence or absence cancer.
- General methodologies for determining expression levels are outlined below, although it will be appreciated that any method for determining expression levels would be suitable.
- Quantitative PCR (qPCR) can be carried out on tumour samples, on serum, plasma and urine samples using BTM specific primers and probes. In controlled reactions, the amount of product formed in a PCR reaction (Sambrook, J., E Fritsch, E. and T Maniatis, Molecular Cloning: A
Laboratory Manual 3rd. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (2001)) correlates with the amount of starting template. Quantification of the PCR product can be carried out by stopping the PCR reaction when it is in log phase, before reagents become limiting. The PCR products are then electrophoresed in agarose or polyacrylamide gels, stained with ethidium bromide or a comparable DNA stain, and the intensity of staining measured by densitometry. Alternatively, the progression of a PCR reaction can be measured using PCR machines such as the Applied Biosystems' Prism 7000 or the Roche LightCycler which measure product accumulation in real-time. Real-time PCR measures either the fluorescence of DNA intercalating dyes such as Sybr Green into the synthesized PCR product, or the fluorescence released by a reporter molecule when cleaved from a quencher molecule; the reporter and quencher molecules are incorporated into an oligonucleotide probe which hybridizes to the target DNA molecule following DNA strand extension from the primer oligonucleotides. The oligonucleotide probe is displaced and degraded by the enzymatic action of the Taq polymerase in the next PCR cycle, releasing the reporter from the quencher molecule. In one variation, known as Scorpion®, the probe is covalently linked to the primer. - RT-PCR can be used to compare RNA levels in different sample populations, in normal and tumour tissues, with or without drug treatment, to characterize patterns of expression, to discriminate between closely related RNAs, and to analyze RNA structure.
- For RT-PCR, the first step is the isolation of RNA from a target sample. The starting material is typically total RNA isolated from human tumours or tumour cell lines, and corresponding normal tissues or cell lines, respectively. RNA can be isolated from a variety of samples, such as tumour samples from breast, lung, colon (e.g., large bowel or small bowel), colorectal, gastric, esophageal, anal, rectal, prostate, brain, liver, kidney, pancreas, spleen, thymus, testis, ovary, uterus, bladder etc., tissues, from primary tumours, or tumour cell lines, and from pooled samples from healthy donors. If the source of RNA is a tumour, RNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g., formalin-fixed) tissue samples.
- The first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction. The two most commonly used reverse transcriptases are avian myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukaemia virus reverse transcriptase (MMLV-RT). The reverse transcription step is typically primed using specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling. For example, extracted RNA can be reverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, CA, USA), following the manufacturer's instructions. The derived cDNA can then be used as a template in the subsequent PCR reaction.
- Although the PCR step can use a variety of thermostable DNA-dependent DNA polymerases, it typically employs the Taq DNA polymerase, which has a 5′-3′ nuclease activity but lacks a 3′-5′ proofreading endonuclease activity. Thus, TaqMan (q) PCR typically utilizes the 5′ nuclease activity of Taq or Tth polymerase to hydrolyze a hybridization probe bound to its target amplicon, but any enzyme with equivalent 5′ nuclease activity can be used.
- Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction. A third oligonucleotide, or probe, is designed to detect nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.
- TaqMan RT-PCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700 Sequence Detection System (Perkin-Elmer-Applied Biosystems, Foster City, Calif., USA), or Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany) In a preferred embodiment, the 5′ nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700tam Sequence Detection System.
- The system consists of a thermocycler, laser, charge-coupled device (CCD), camera, and computer. The system amplifies samples in a 96-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fibre optics cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.
- 5′ nuclease assay data are initially expressed as Ct, or the threshold cycle. As discussed above, fluorescence values are recorded during every cycle and represent the amount of product amplified to that point in the amplification reaction. The point when the fluorescent signal is first recorded as statistically significant is the threshold cycle.
- A more recent variation of the RT-PCR technique is the real time quantitative PCR, which measures PCR product accumulation through a dual-labeled fluorigenic probe (i.e., TaqMan probe). Real time PCR is compatible both with quantitative competitive PCR and with quantitative comparative PCR. The former uses an internal competitor for each target sequence for normalization, while the latter uses a normalization gene contained within the sample, or a housekeeping gene for RT-PCR. Further details are provided, e.g., by Held et al., Genome Research 6: 986-994 (1996).
- Expression levels can be determined using fixed, paraffin-embedded tissues as the RNA source. According to one aspect of the present invention, PCR primers and probes are designed based upon intron sequences present in the gene to be amplified. In this embodiment, the first step in the primer/probe design is the delineation of intron sequences within the genes. This can be done by publicly available software, such as the DNA BLAT software developed by Kent, W. J., Genome Res. 12 (4): 656-64 (2002), or by the BLAST software including its variations. Subsequent steps follow well established methods of PCR primer and probe design.
- In order to avoid non-specific signals, it is useful to mask repetitive sequences within the introns when designing the primers and probes. This can be easily accomplished by using the Repeat Masker program available on-line through the Baylor College of Medicine, which screens DNA sequences against a library of repetitive elements and returns a query sequence in which the repetitive elements are masked. The masked sequences can then be used to design primer and probe sequences using any commercially or otherwise publicly available primer/probe design packages, such as Primer Express (Applied Biosystems); MGB assay-by-design (Applied Biosystems); Primer3 (Steve Rozen and Helen J. Skaletsky (2000) Primer3 on the WWW for general users and for biologist programmers in: Krawetz S, Misener S (eds) Bioinformatics Methods and Protocols: Methods in Molecular Biology. Humana Press, Totowa, N.J., pp 365-386).
- The most important factors considered in PCR primer design include primer length, melting temperature (Tm), and G/C content, specificity, complementary primer sequences, and 3′ end sequence. In general, optimal PCR primers are generally 17-30 bases in length, and contain about 20-80%, such as, for example, about 50-60% G+C bases. Melting temperatures between 50 and 80° C., e.g., about 50 to 70° C., are typically preferred. For further guidelines for PCR primer and probe design see, e.g., Dieffenbach, C. W. et al., General Concepts for PCR Primer Design in: PCR Primer, A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1995, pp. 133-155; Innis and Gelfand, Optimization of PCRs in: PCR Protocols, A Guide to Methods and Applications, CRC Press, London, 1994, pp. 5-11; and Plasterer, T. N. Primerselect: Primer and probe design. Methods Mol. Biol. 70: 520-527 (1997), the entire disclosures of which are hereby expressly incorporated by reference.
- Differential expression can also be identified, or confirmed using the microarray technique. Thus, the expression profile of CCPMs can be measured in either fresh or paraffin-embedded tumour tissue, using microarray technology. In this method, polynucleotide sequences of interest (including cDNAs and oligonucleotides) are plated, or arrayed, on a microchip substrate. The arrayed sequences (i.e., capture probes) are then hybridized with specific polynucleotides from cells or tissues of interest (i.e., targets). Just as in the RT-PCR method, the source of RNA typically is total RNA isolated from human tumours or tumour cell lines, and corresponding normal tissues or cell lines. Thus RNA can be isolated from a variety of primary tumours or tumour cell lines. If the source of RNA is a primary tumour, RNA can be extracted, for example, from frozen or archived formalin fixed paraffin-embedded (FFPE) tissue samples and fixed (e.g., formalin-fixed) tissue samples, which are routinely prepared and preserved in everyday clinical practice.
- In a specific embodiment of the microarray technique, PCR amplified inserts of cDNA clones are applied to a substrate. The substrate can include up to 1, 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, or 75 nucleotide sequences. In other aspects, the substrate can include at least 10,000 nucleotide sequences. The microarrayed sequences, immobilized on the microchip, are suitable for hybridization under stringent conditions. As other embodiments, the targets for the microarrays can be at least 50, 100, 200, 400, 500, 1000, or 2000 bases in length; or 50-100, 100-200, 100-500, 100-1000, 100-2000, or 500-5000 bases in length. As further embodiments, the capture probes for the microarrays can be at least 10, 15, 20, 25, 50, 75, 80, or 100 bases in length; or 10-15, 10-20, 10-25, 10-50, 10-75, 10-80, or 20-80 bases in length.
- Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest. Labeled cDNA probes applied to the chip hybridize with specificity to each spot of DNA on the array. After stringent washing to remove non-specifically bound probes, the chip is scanned by confocal laser microscopy or by another detection method, such as a CCD camera. Quantitation of hybridization of each arrayed element allows for assessment of corresponding mRNA abundance. With dual colour fluorescence, separately labeled cDNA probes generated from two sources of RNA are hybridized pairwise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously. An exemplary protocol for this is described in detail in Example 4.
- The miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes. Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al., Proc. Natl. Acad. Sci. USA 93 (2): 106-149 (1996)). Microarray analysis can be performed by commercially available equipment, following manufacturer's protocols, such as by using the Affymetrix GenChip technology, Illumina microarray technology or Incyte's microarray technology. The development of microarray methods for large-scale analysis of gene expression makes it possible to search systematically for molecular markers of cancer classification and outcome prediction in a variety of tumour types.
- General methods for mRNA extraction are well known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et al., Current Protocols of Molecular Biology, John Wiley and Sons (1997). Methods for RNA extraction from paraffin embedded tissues are disclosed, for example, in Rupp and Locker, Lab Invest. 56: A67 (1987), and De Sandres et al., BioTechniques 18: 42044 (1995). In particular, RNA isolation can be performed using purification kit, buffer set, and protease from commercial manufacturers, such as Qiagen, according to the manufacturer's instructions. For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini-columns. Other commercially available RNA isolation kits include MasterPure Complete DNA and RNA Purification Kit (EPICENTRE (D, Madison, Wis.), and Paraffin Block RNA Isolation Kit (Ambion, Inc.). Total RNA from tissue samples can be isolated using RNA Stat-60 (Tel-Test). RNA prepared from tumour can be isolated, for example, by cesium chloride density gradient centrifugation.
- The steps of a representative protocol for profiling gene expression using fixed, paraffin-embedded tissues as the RNA source, including mRNA isolation, purification, primer extension and amplification are given in various published journal articles (for example: T. E. Godfrey et al. J. Molec. Diagnostics 2: 84-91 (2000); K. Specht et al., Am. J. Pathol. 158: 419-29 (2001)). Briefly, a representative process starts with cutting about 10 μm thick sections of paraffin-embedded tumour tissue samples. The RNA is then extracted, and protein and DNA are removed. After analysis of the RNA concentration, RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR. Finally, the data are analyzed to identify the best treatment option(s) available to the patient on the basis of the characteristic gene expression pattern identified in the tumour sample examined.
- Immunohistochemistry methods are also suitable for detecting the expression levels of the proliferation markers of the present invention. Thus, antibodies or antisera, preferably polyclonal antisera, and most preferably monoclonal antibodies specific for each marker, are used to detect expression. The antibodies can be detected by direct labeling of the antibodies themselves, for example, with radioactive labels, fluorescent labels, hapten labels such as, biotin, or an enzyme such as horse radish peroxidase or alkaline phosphatase. Alternatively, unlabeled primary antibody is used in conjunction with a labeled secondary antibody, comprising antisera, polyclonal antisera or a monoclonal antibody specific for the primary antibody. Immunohistochemistry protocols and kits are well known in the art and are commercially available.
- Proteomics can be used to analyze the polypeptides present in a sample (e.g., tissue, organism, or cell culture) at a certain point of time. In particular, proteomic techniques can be used to assess the global changes of polypeptide expression in a sample (also referred to as expression proteomics). Proteomic analysis typically includes: (1) separation of individual polypeptides in a sample by 2-D gel electrophoresis (2-D PAGE); (2) identification of the individual polypeptides recovered from the gel, e.g., by mass spectrometry or N-terminal sequencing, and (3) analysis of the data using bioinformatics. Proteomics methods are valuable supplements to other methods of gene expression profiling, and can be used, alone or in combination with other methods, to detect the products of the proliferation markers of the present invention.
- These methods involve binding the nucleic acid probe to a support, and hybridizing under appropriate conditions with RNA or cDNA derived from the test sample (Sambrook, J., E Fritsch, E. and T Maniatis, Molecular Cloning: A
Laboratory Manual 3rd. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (2001)). These methods can be applied to BTM derived from a tumour tissue or fluid sample. The RNA or cDNA preparations are typically labeled with a fluorescent or radioactive molecule to enable detection and quantification. In some applications, the hybridizing DNA can be tagged with a branched, fluorescently labeled structure to enhance signal intensity (Nolte, F. S., Branched DNA signal amplification for direct quantitation of nucleic acid sequences in clinical specimens. Adv. Clin. Chem. 33, 201-35 (1998)). Unhybridized label is removed by extensive washing in low salt solutions such as 0.1×SSC, 0.5% SDS before quantifying the amount of hybridization by fluorescence detection or densitometry of gel images. The supports can be solid, such as nylon or nitrocellulose membranes, or consist of microspheres or beads that are hybridized when in liquid suspension. To allow washing and purification, the beads may be magnetic (Haukanes, B-I and Kvam, C., Application of magnetic beads in bioassays. Bio/Technology 11, 60-63 (1993)) or fluorescently-labeled to enable flow cytometry (see for example: Spiro, A., Lowe, M. and Brown, D., A Bead-Based Method for Multiplexed Identification and Quantitation of DNA Sequences Using Flow Cytometry. Appl. Env. Micro. 66, 4258-4265 (2000)). - A variation of hybridization technology is the QuantiGene Plex® assay (Genospectra, Fremont) which combines a fluorescent bead support with branched DNA signal amplification. Still another variation on hybridization technology is the Quantikine® mRNA assay (R&D Systems, Minneapolis). Methodology is as described in the manufacturer's instructions. Briefly the assay uses oligonucleotide hybridization probes conjugated to Digoxigenin. Hybridization is detected using anti-Digoxigenin antibodies coupled to alkaline phosphatase in colorometric assays.
- Additional methods are well known in the art and need not be described further herein.
- Briefly, in sandwich ELISA assays, a polyclonal or monoclonal antibody against the BTM is bound to a solid support (Crowther, J. R. The ELISA guidebook. Humana Press: New Jersey (2000); Harlow, E. and Lane, D., Using antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (1999)) or suspension beads. Other methods are known in the art and need not be described herein further. Monoclonal antibodies can be hybridoma-derived or selected from phage antibody libraries (Hust M. and Dubel S., Phage display vectors for the in vitro generation of human antibody fragments. Methods Mol Biol. 295:71-96 (2005)). Non-specific binding sites are blocked with non-target protein preparations and detergents. The capture antibody is then incubated with a preparation of urine or tissue containing the BTM antigen. The mixture is washed before the antibody/antigen complex is incubated with a second antibody that detects the target BTM. The second antibody is typically conjugated to a fluorescent molecule or other reporter molecule that can either be detected in an enzymatic reaction or with a third antibody conjugated to a reporter (Crowther, Id.). Alternatively, in direct ELISAs, the preparation containing the BTM can be bound to the support or bead and the target antigen detected directly with an antibody-reporter conjugate (Crowther, Id.).
- Methods for producing monoclonal antibodies and polyclonal antisera are well known in the art and need not be described herein further.
- The methods can also be used for immunodetection of marker family members in sera or plasma from bladder cancer patients taken before and after surgery to remove the tumour, immunodetection of marker family members in patients with other cancers, including but not limited to, colorectal, pancreatic, ovarian, melanoma, liver, oesophageal, stomach, endometrial, and brain and immunodetection of marker family members in urine and stool from bladder cancer patients.
- BTMs can also be detected in tissues or urine using other standard immunodetection techniques such as immunoblotting or immunoprecipitation (Harlow, E. and Lane, D., Using antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (1999)). In immunoblotting, protein preparations from tissue or fluid containing the BTM are electrophoresed through polyacrylamide gels under denaturing or non-denaturing conditions. The proteins are then transferred to a membrane support such as nylon. The BTM is then reacted directly or indirectly with monoclonal or polyclonal antibodies as described for immunohistochemistry. Alternatively, in some preparations, the proteins can be spotted directly onto membranes without prior electrophoretic separation. Signal can be quantified by densitometry.
- In immunoprecipitation, a soluble preparation containing the BTM is incubated with a monoclonal or polyclonal antibody against the BTM. The reaction is then incubated with inert beads made of agarose or polyacrylamide with covalently attached protein A or protein G. The protein A or G beads specifically interact with the antibodies forming an immobilized complex of antibody-BTM-antigen bound to the bead. Following washing the bound BTM can be detected and quantified by immunoblotting or ELISA.
- For tests using down-regulated BTMs in either ratios or regression analyses, thresholds will be derived that will enable a sample to be called either positive or negative for TCC. These thresholds will be determined by the analysis of cohorts of patients who are being investigated for the presence of TCC. Thresholds may vary for different test applications; for example, thresholds for use of the test in population screening will be determined using cohorts of patients who are largely free of urological symptoms, and these thresholds may be different to those used in tests for patients who are under surveillance for TCC recurrence, or those being investigated for the presence of urological symptoms such as hematuria. A threshold could be selected to provide a practical level of test specificity in the required clinical setting; that is, a specificity that allows reasonable sensitivity without excessive numbers of patients receiving false positive results. This specificity may be within the range of 80-90%. An alternative method to obtain a test threshold is to plot sensitivity against specificity for different test thresholds (ROC curves) then select the point of inflexion of the curve.
- As an alternative to single thresholds, the test may use test intervals which provide different degrees of likelihood of presence of disease and which have different clinical consequences associated with them. For example, a test may have three intervals; one associated with a high (eg 90%) risk of the presence of TCC, a second associated with a low risk of TCC and a third regarded as being suspicious of disease. The “suspicious” interval could be associated with a recommendation for a repeat test in a defined period of time.
- In several embodiments, assays for BTM can be desirably carried out on urine samples. In general, methods for assaying for oligonucleotides, proteins and peptides in these fluids are known in the art. However, for purposes of illustration, urine levels of a BTM can be quantified using a sandwich-type enzyme-linked immunosorbent assay (ELISA). For plasma or serum assays, a 5 μL aliquot of a properly diluted sample or serially diluted standard BTM and 75 μL of peroxidase-conjugated anti-human BTM antibody are added to wells of a microtiter plate. After a 30-minute incubation period at 30° C., the wells are washed with 0.05
% Tween 20 in phosphate-buffered saline (PBS) to remove unbound antibody. Bound complexes of BTM and anti-BTM antibody are then incubated with o-phenylendiamine containing H2O2 for 15 minutes at 30° C. The reaction is stopped by adding 1 M H2SO4, and the absorbance at 492 nm is measured with a microtiter plate reader. It can be appreciated that anti-BTM antibodies can be monoclonal antibodies or polyclonal antisera. - Because many proteins are either (1) secreted by cells, (2) cleaved from cell membranes, (3) lost from cells upon cell death or (4) contained within sloughed cells, it will be appreciated that BTMs may also be detected in the urine. Additionally, diagnosis of bladder cancer can be determined by measuring either expression of BTMs in a sample, or accumulation of BTMs in a sample. Prior art methods of diagnosis include cystoscopy, cytology and examination of cells extracted during these procedures. Such methods have relied upon identification of tumour cells in the urine or in a brush sample of urothelium, or in other cases, in biopsy specimens of the bladder wall. These methods suffer from several types of errors, including sampling error, errors in identification between observers, and the like.
- In additional aspects, this invention includes manufacture of antibodies against BTMs. Using methods described herein, novel BTMs can be identified using microarray and/or qPCR methods. Once a putative marker is identified, it can be produced in sufficient amount to be suitable for eliciting an immunological response. In some cases, a full-length BTM can be used, and in others, a peptide fragment of a BTM may be sufficient as an immunogen. The immunogen can be injected into a suitable host (e.g., mouse, rabbit, etc) and if desired, an adjuvant, such as Freund's complete adjuvant, Freund's incomplete adjuvant can be injected to increase the immune response. It can be appreciated that making antibodies is routine in the immunological arts and need not be described herein further. As a result, one can produce antibodies against BTMs identified using methods described herein.
- In yet further embodiments, antibodies can be made against the protein or the protein core of the tumour markers identified herein or against an oligonucleotide sequence unique to a BTM. Although certain proteins can be glycosylated, variations in the pattern of glycosylation can, in certain circumstances, lead to mis-detection of forms of BTMs that lack usual glycosylation patterns. Thus, in certain aspects of this invention, BTM immunogens can include deglycosylated BTM or deglycosylated BTM fragments. Deglycosylation can be accomplished using one or more glycosidases known in the art. Alternatively, BTM cDNA can be expressed in glycosylation-deficient cell lines, such as prokaryotic cell lines, including E. coli and the like.
- Vectors can be made having BTM-encoding oligonucleotides therein. Many such vectors can be based on standard vectors known in the art. Vectors can be used to transfect a variety of cell lines to produce BTM-producing cell lines, which can be used to produce desired quantities of BTM for development of specific antibodies or other reagents for detection of BTMs or for standardizing developed assays for BTMs.
- Based on the discoveries of this invention, several types of test kits can be envisioned and produced. First, kits can be made that have a detection device pre-loaded with a detection molecule (or “capture reagent”). In embodiments for detection of BTM mRNA, such devices can comprise a substrate (e.g., glass, silicon, quartz, metal, etc) on which oligonucleotides as capture reagents that hybridize with the mRNA to be detected is bound. In some embodiments, direct detection of mRNA can be accomplished by hybridizing mRNA (labeled with cy3, cy5, radiolabel or other label) to the oligonucleotides on the substrate. In other embodiments, detection of mRNA can be accomplished by first making complementary DNA (cDNA) to the desired mRNA. Then, labeled cDNA can be hybridized to the oligonucleotides on the substrate and detected.
- Antibodies can also be used in kits as capture reagents. In some embodiments, a substrate (e.g., a multiwell plate) can have a specific BTM capture reagent attached thereto. In some embodiments, a kit can have a blocking reagent included. Blocking reagents can be used to reduce non-specific binding. For example, non-specific oligonucleotide binding can be reduced using excess DNA from any convenient source that does not contain BTM oligonucleotides, such as salmon sperm DNA. Non-specific antibody binding can be reduced using an excess of a blocking protein such as serum albumin It can be appreciated that numerous methods for detecting oligonucleotides and proteins are known in the art, and any strategy that can specifically detect BTM associated molecules can be used and be considered within the scope of this invention.
- In addition to a substrate, a test kit can comprise capture reagents (such as probes), washing solutions (e.g., SSC, other salts, buffers, detergents and the like), as well as detection moieties (e.g., cy3, cy5, radiolabels, and the like). Kits can also include instructions for use and a package.
- In one series of embodiments, reagents for the testing the BTM LTBDH4 in combination with over-expressing BTMs can be incorporated into a kit for the testing of unfractionated urine or urine cell sediments to detect bladder cancer. The urine samples could be collected from patients with diagnosed bladder cancer who require monitoring for disease progression or treatment response, individuals with urological symptoms including macroscopic or microscopic hematuria, or asymptomatic individuals. For patients or individuals being tested with a kit that measures the BTMs in unfractionated urine, approximately 2 mls of urine can be taken for testing. For tests on the urine pellet, >10 mls of urine can be collected.
- A suitable kit includes: (i) instructions for use and result interpretation, (ii) software for interpretation of multiple gene analyses, including any regression analysis classifier or formula (iii) reagents for the stabilization and purification of RNA from unfractionated urine or urine pellets, (iv) reagents for the synthesis of cDNA including dNTPs and reverse transcriptase, and (v) reagents for the quantification of the BTM cDNA. In one form, these reagents would be used for quantitative PCR and would include specific exon-spanning oligonucleotide primers, a third oligonucleotide labeled with a probe for detection, Taq polymerase and the other buffers, salts and dNTPs required for PCR. The kit can also use other methods for detection of the transcripts such as direct hybridization of the BTM RNA with labeled probes or branched DNA technology; and (vi) oligonucleotides and probe for the detection of transcripts from a highly transcribed gene, such as β-actin, to serve as a quality control measure.
- To evaluate the progression of bladder tumours, samples of tissue are obtained by biopsy of bladder wall or samples of urine are collected over time from a patient having bladder cancer. Evaluation of the ratio of BTMs or combinations thereof are made for samples taken at different times. BTM ratios within a specified range are indicative of progression of bladder cancer.
- To evaluate the efficacy of therapy for bladder tumours, samples of tissue and/or urine are obtained before treatment is initiated. The baseline levels of one or more BTMs are determined, as are ratios of various BTMs with respect to each other. Treatment is initiated, and can include any therapy known in the art, including surgery, radiation therapy or chemotherapy as appropriate to the type and stage of the disease. During the course of therapy, samples of tissue and/or urine are collected and analyzed for the presence and amount of BTMs. Ratios of various BTMs are determined and results are compared to: (1) the patient's baseline levels before treatment or (2) normal values obtained from a population of individuals not having bladder cancer.
- In addition to the rapid diagnosis and early detection of TCC, BTM marker ratios detected in either tissue, serum or urine can be used to monitor a patient's response to therapy. In these applications, urine and/or serum samples can be taken at intervals following the initiation of systemic, intravesicular or intravascular chemotherapy, radiotherapy or immunotherapy. A change in marker ratio can indicate a reduction in tumour size, indicative of effective treatment. The rate of change can be used to predict the optimum therapeutic dose for each patient or treatment.
- In addition to the BTM ratios, regression or classification analyses that include high and low expressing BTM family members can be used for the applications described above.
- Markers evaluated are selected from known human genes. The genes evaluated are indicated in
FIGS. 3 and 4 . Included inFIGS. 3 and 4 are the name of the gene, the HUGO identifier, MWG oligo number, NCBI mRNA reference sequence number and the protein reference number. The full length sequences can be found at http_:_//_www_._ncbi_._nlm_._nih_._gov_/_entrez/. - The examples described herein are for purposes of illustrating embodiments of the invention and are not intended to limit the scope of the invention. Other embodiments, methods and types of analyses are within the scope of persons of ordinary skill in the molecular diagnostic arts and need not be described in detail hereon. Other embodiments within the scope of the art that are based on the teachings herein are considered to be part of this invention.
- Bladder tumour samples and non-malignant urothelium samples were collected from surgical specimens resected at Kyoto University Hospital, Japan.
- Urine samples from non-malignant controls and bladder cancer patients were obtained from Kyoto University Hospital, Japan. Healthy control samples were obtained from Japanese volunteers (
FIG. 1 ). - Tumour tissues were homogenized in a TriReagent:water (3:1) mix, then chloroform extracted. Total RNA was then purified from the aqueous phase using the RNeasy™ procedure (Qiagen). RNA was also extracted from 16 cancer cell lines and pooled to serve as a reference RNA.
- RNA was extracted from urine by mixing the urine sample with an equal volume of lysis buffer (5.64M guanidine-HCl, 0.5% sarkosyl, 50 mM sodium acetate (pH 6.5) and 1 mM β-mercaptoethanol; pH adjusted to 7.0 with 1.5M Hepes pH 8). Due to the low amounts of RNA in urine, 7.5 ugs of total bacterial RNA was added to the urine/lysis buffer mix to act as a carrier. Total RNA was then extracted using Trizol and the RNeasy™ procedure. RNA preparations were further purified prior to cDNA synthesis using the Qiagen QIAquick™ PCR purification kit.
- RNA was extracted from the blood of three healthy volunteers by performing a Trizol/RNeasy™ extraction on cells enriched from whole blood using sedimentation in 3.6% dextran.
- Epoxy coated glass slides (MWG Biotech) were printed with ˜30,000 50mer oligonucleotides (MWG Biotech) using a Gene Machines microarraying robot, according to the manufacturer's protocol.
- cDNA was transcribed from 5 μg total RNA using Superscript II™ reverse transcriptase (Invitrogen) in reactions containing 5-(3-aminoallyl)-2′ deoxyuridine-5′-triphosphate. The reaction was then de-ionised in a Microcon column before being incubated with Cy3 or Cy5 in bicarbonate buffer for 1 hour at room temperature. Unincorporated dyes were removed using a Qiaquick column (Qiagen) and the sample concentrated to 15 μl in a SpeedVac. Cy3 and Cy5 labeled cDNAs were then mixed with Ambion ULTRAhyb™ buffer, denatured at 100° C. for 2 min and hybridized to the microarray slides in hybridisation chambers at 42° C. for 16 hours. The slides were then washed and scanned twice in an Axon 4000A™ scanner at two power settings.
- RNA from 53 bladder tumours and 20 non-malignant (“normal”) bladder tissue samples were labeled with Cy5 and hybridized in duplicate or triplicate with Cy3 labeled reference RNA. After normalization, the change in expression in each of 29,718 genes was then estimated by fold change and statistical probability.
- Median fluorescence intensities detected by Genepix™ software were corrected by subtraction of the local background intensities. Spots with a background corrected intensity of less than zero were excluded. To facilitate normalization, intensity ratios and overall spot intensities were log-transformed. The logged intensity ratios were corrected for dye and spatial bias using local regression implemented in the LOCFIT™ package. Logged intensity ratios were regressed simultaneously with respect to overall spot intensity and location. The residuals of the local regression provided the corrected logged fold changes. For quality control, ratios of each normalized microarray were plotted in respect to spot intensity and localization. The plots were subsequently visually inspected for any remaining artifacts. Additionally, an ANOVA model was applied for the detection of pin-tip bias. All results and parameters of the normalization were inserted into a Postgres-database for statistical analysis.
- To improve the comparison of measured fold changes between arrays, log2 (ratios) were scaled to have the same overall standard deviation per array. This standardization reduced the average within-tissue class variability. A rank-test based on fold changes was then used to improve the noise robustness. This test consists of two steps: (i) calculation of the rank of fold change (Rfc) within arrays and ii) subtraction of the median (Rfc) for normal tissue from the median (Rfc) for tumour tissue. The difference of both median ranks defines the score of the fold change rank. Three additional statistical tests were also performed on standardized data: 1) Two sample student's t-test, 2) the Wilcoxon test and 3) Statistical Analysis of Microarrays (SAM). The most significantly down-regulated genes determined by each of the statistical methods (rank fold change, t-test, Wilcoxon test, and SAM) were given a rank score for each test. All rank scores were then added into one summated rank score.
- Total urine RNA was annealed to gene-specific primers for each of the bladder tumour markers by incubating at 70° C. then cooling on ice for 2 mins in 50 μl reactions containing forward primers at 0.01 μg/μl. Each cDNA reaction contained annealed RNA and 4 μl of 5× Superscript II reverse transcriptase buffer (Invitrogen, USA), 2 μl of 0.1M DTT (Invitrogen, USA), 0.5 μl of RNase out (40U/μL), (Invitrogen, USA), 4 μl of 10 mM dNTP (Invitrogen, USA) and 0.5 μl of Superscript II reverse transcriptase (200U/μl), (Invitrogen, USA) in a final volume of 20 μl. Reactions were incubated at 42° C. for 1 hour, 10 minutes at 70° C. and 1 minute at 80° C. Reactions were cleaned prior to qPCR with Qiagen QIAquick PCR purification columns (Qiagen, Victoria, Australia) and stored at −80° C.
- Real-time or quantitative PCR (qPCR) is used for absolute or relative quantitation of PCR template copy number. Taqman™ probe and primer sets were designed using Primer Express V 2.0™ (Applied Biosystems). Where possible, all potential splice variants were included in the resulting amplicon, with amplicon preference given to regions covered by the MWG-Biotech-derived microarray oligonucleotide. Primer and probe sequences are shown in
FIG. 2 . Alternatively, if the target gene was represented by an Assay-on-Demand™ expression assay (Applied Biosystems) covering the desired amplicons, these were used. In the in-house designed assays, primer concentration was titrated using a SYBR green labeling protocol and cDNA made from the reference RNA Amplification was carried out on an ABI Prism™ 7000 sequence detection system under standard cycling conditions. When single amplification products were observed in the dissociation curves, standard curves were generated over a 625 fold concentration range using optimal primer concentrations and 5′FAM-3′TAMRA phosphate Taqman™ probe (Proligo) at a final concentration of 250 nM. Assays giving standard curves with regression coefficients over 0.98 were used in subsequent analyses. - Assays were performed in 96 well plates. Each plate contained a reference cDNA standard curve, over a 625-fold concentration range. For the urine qPCR, total RNA extracted from ˜0.5 mls unfractionated urine was used in each reaction. The ΔCt (target gene Ct—mean reference cDNA Ct) was calculated for each marker, and used in subsequent ratios, regression or classification analysis.
- The expression of the markers shown in
FIGS. 3 and 4 in whole blood was determined in silico. Microarray probes were linked to UniGene clusters via the GenBank accession numbers of their target mRNAs, and the tissue expression profile from UniGene used to determine the number of expressed sequence tags (ESTs) in blood libraries. Only genes with 0 or 1 expressed sequence tags (EST) are shown inFIG. 4 . To confirm the low expression of LTB4DH in whole blood, RT-qPCR was carried out on total RNA extracted from whole blood using the primers and probes shown inFIG. 2 . No significant expression was observed (results not shown). - To identify down-regulated markers of bladder cancer, we performed microarray studies on RNA from 53 bladder tumours and 20 non-malignant bladder tissue samples using 30,000 oligonucleotide chips.
FIG. 3 shows the statistical analysis of microarray data for 300 genes that show significant downregulation in bladder cancer tissue compared to non-malignant tissue.FIG. 3 includes the HUGO gene name and symbol, the protein reference sequence number, the NCBI mRNA reference sequence number, the MWG Biotech probe oligonucleotide number, the median fold change in gene expression between tumour and non-malignant tissue, the results of an original unadjusted Student's t-test, the results of the 2-sample Wilcoxon test, the results of the SAM test, and the summated rank score. - Because urinary hematuria is a common co-occurrence with bladder cancer, it is an advantage that bladder cancer markers are not significantly elevated in whole blood. In addition, because the downregulated markers are being used in ratios, regression or classification analysis, it is an advantage that they be present in sufficiently high copy numbers in both tumour cells and non-malignant bladder cells to enable reliable detection in urine. To identify suitable markers, we screened the genes in
FIG. 3 for a subset that had little or no representation in blood EST libraries, and had higher than median expression in non-malignant tissue. Median expression was estimated by ranking the 30,000 oligonucleotides on the array by their median intensity in the samples analysed in the microarray study. Markers that met the criteria are shown inFIG. 4 .FIG. 4 includes the HUGO gene name and symbol, the protein reference sequence number, the NCBI mRNA reference sequence number, the median fold change, the rank score, the median rank of microarray spot intensity in tumour tissue and non-malignant tissue, and the number of ESTs present in blood EST libraries. - The down regulation observed in the array data was validated by qPCR for three genes shown in
FIG. 4 , LTB4DH, BAG1 and FLJ21511. These genes were tested on total RNA from 10 tumour samples and 10 non-malignant samples. LTB4DH, BAG1 and FLJ21511 showed an average downregulation in bladder tumours compared to bladder non-malignant tissue of 2.5 fold, 1.4 fold and 6.1 fold, respectively, in these samples. - Urine from TCC patients and controls with non-malignant urological conditions was collected by either voiding or catheterisation. Total RNA was extracted from the voided urine of 42 controls and the voided or catheterised urine of 37 TCC patients and used in quantitative RT-PCR using primers and probes for LTB4DH and three over-expressed markers, IGFBP5, MDK and HoxA13. The ΔCt ratios were determined for IGFBP5/LTB4DH, MDK/LTB4DH and HoxA13/LTB4DH. This data is illustrated by the box plots in
FIG. 5 , which show a clear difference in the spread of data between the urine samples from controls and TCC patients for each of the three tests. The most accurate test was IGFBP5/LTB4DH which demonstrated sensitivity and specificity of 87% and 88% in this sample cohort, respectively (FIG. 6a ). To illustrate the correspondence between sensitivity and specificity for each of these tests, ROC curves are shown inFIGS. 7A-7C . The areas under the curve for IGFBP5/LTB4DH, MDK/LTB4DH and HoxA13/LTB4DH are 0.9223, 0.9199, and 0.7497, respectively. These areas, which measure test accuracy, indicate that all three ratios with LTB4DH are useful tests, in particular IGFBP5/LTB4DH and MDK/LTB4DH. - To increase the sensitivity and specificity of TCC detection, combinations of two tests were used. The optimal sensitivities and specificities of these test combinations are shown in
FIG. 6B .FIGS. 8A-8F shows the separation of data in 2 dimensional space for each of the three tests using LTB4DH and BAG1. This data shows that combinations of two or more tests that include either of the downregulated BTMs LTB4DH or BAG1, are able to achieve sensitivities and specificities of over 90%. Moreover, because these tests are measuring simple gene expression signatures and not absolute levels of markers, they will be robust to variations in urine concentration. - To demonstrate the robustness of tests involving ratios with LTB4DH to urine concentration, the levels of IGFBP5 alone (ΔCt) and IGFBP5/LTB4DH were plotted as a function of urine concentration (
FIG. 9a-b ) and trendlines fitted to the data. It can be seen that for both urine samples from non-malignant controls and patients with TCC, there is a decrease in the IGFBP5 ΔCt with increasing urine concentration that is absent in the IGFBP5/LTB4DH ratio. The effect is most pronounced with the non-malignant samples because of the absence of other influences such as tumour size and tumour heterogeneity in the expression of IGFBP5 and LTB4DH. - In some instances, when single markers are used in bladder cancer assays, the method of urine sample collection can affect the amount of marker detected due to variations in the number of exfoliated bladder cells collected. This bias could lead to false positive or false negative results in a small proportion of samples. The use of ratios including LTB4DH or other low-expressing genes should provide a method to compensate for different methods. To test this hypothesis, samples collected from TCC patients by either simple voiding (nine samples) or catheterisation (28 samples) were tested for the presence of TCC markers and LTB4DH. Analysis of the TCC markers alone showed that the voided samples were more heavily represented at the lower end of the range of data (higher Ct), consistent with a lower average number of exfoliated cells in these samples compared to the catheterised samples. This is illustrated in the self-self scatter plots for IGFBP5, MDK and HoxA13 in
FIG. 10a-c . In contrast, when ratios between these markers and LTB4DH were calculated, the voided and catheterised samples were spread over similar ranges of Ct ratios (FIG. 10d-f ), illustrating that the calculation of gene expression signatures between high expressing markers and low expressing markers such as LTB4DH compensate for variations in marker levels introduced by different urine sampling methodologies. - Urine samples from patients with low grade tumours are often borderline in their accumulation of BTMs due to the presence of only small numbers of exfoliated cells in these samples. These samples are therefore at high risk of being incorrectly classified due to variations in sampling method or urine concentration.
- The utility of gene expression ratios that incorporate down-regulated genes for the detection of TCC is therefore likely to be pronounced when applied to the detection of low grade TCC. To demonstrate this effect, a cohort of voided 43 urine samples from patients with low grade TCC and 123 controls were tested with the markers IGFBP5, HoxA13 and LTB4DH. The clinical characteristics of the cohort are summarised in
FIG. 13 . The qPCR data for IGFBP5 and HoxA13 were analysed alone and in ratios with LTB4DH using the area under the ROC curve as a measure of test accuracy (STATA statistics package). The results are summarized inFIG. 14 . Using the IGFBP5 marker, LTB4DH increased the accuracy of detection of low grade (grade 1-2) stage Ta TCCs by 9% and low grade TCCs of any stage by 8%. The accuracy of HoXA13 testing of low grade stage Ta TCCs was increased by 3%. - Linear discriminate analysis (LDA) is a statistical technique (Fisher R. A. “The Use of Multiple Measurements in Taxonomic Problems”, Annals of
Eugenics 7 179 (1936)) in which a linear combination of variables is generated, such that there is maximal separation between two or more groups. This linear combination of variables is termed the “linear discriminant”, which is a linear function of the input variables that maximally separates the classes of the data set. The ability of LDA (or any other classification technique) to characterise a particular dataset, such as qPCR data, can be tested using cross-validation. In this method, part of the dataset is used to generate a classifier, and part of the dataset is used to measure the effectiveness of that classifier. The partitioning of the dataset into training and testing sets can be repeated multiple times (each time generating a new classifier). In k-fold cross-validation, the dataset is split k-wise, and each subset is used as the testing set in one of k rounds of training and validation. This can be extended to leave-one-out cross-validation (LOOCV) where each sample is classified according to a classifier generated from the remaining samples in the dataset (“leaving one out”; leaving out the sample which is being tested). - LDA and LOOCV were used to illustrate the utility of the downregulated BTM, LTB4DH, in improving the diagnosis of TCC. qPCR was first carried out on the cohort of control and TCC urine samples described in
FIG. 13 which were supplemented with an additional 30grade 3 tumours (5>stage stage - The sensitivity of detection of TCC using combinations of upregulated BTMs with and without LTB4DH was determined at a specificity of 85%. The results of this analysis are shown in
FIG. 15 . It can be seen that the addition of LTB4DH to assays including combinations of the upregulated BTMs MDK, IGFBP5, Top2a, cdc2 and HoxA13 increased the overall sensitivity by 1-2% and the sensitivity of detection of Stage Ta tumours, grade 1-2 tumours andgrade 3 tumours by up to 3%. - Wherein in the foregoing description reference has been made to integers or components having known equivalents, such equivalents are herein incorporated as if individually set fourth.
- Although the invention has been described by way of example and with reference to possible embodiments thereof, it is to be appreciated that improvements and/or modifications may be made without departing from the scope or the spirit thereof.
- Methods for detecting BTM family members include detection of nucleic acids, proteins and peptides using microarray and/or real time PCR methods. The compositions and methods of this invention are useful in diagnosis of disease, evaluating efficacy of therapy, and for producing reagents and test kits suitable for measuring expression of BTM family members.
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/798,922 US10689711B2 (en) | 2006-02-10 | 2017-10-31 | Test kits and methods for their use to detect genetic markers for urothelial carcinoma of the bladder and treatment thereof |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ545243 | 2006-02-10 | ||
NZ545243A NZ545243A (en) | 2006-02-10 | 2006-02-10 | Urine gene expression ratios for detection of cancer |
PCT/NZ2007/000029 WO2007091904A1 (en) | 2006-02-10 | 2007-02-09 | Urine gene expression ratios for detection of cancer |
NZPCT/NZ2007/000029 | 2007-08-16 | ||
WOPCT/NZ2007/000029 | 2007-08-16 | ||
US12/221,626 US20090098553A1 (en) | 2006-02-10 | 2008-08-05 | Urine gene expression ratios for detection of cancer |
US12/843,435 US9702009B2 (en) | 2006-02-10 | 2010-07-26 | Urine gene expression ratios for detection of cancer |
US14/920,552 US9809860B2 (en) | 2006-02-10 | 2015-10-22 | Test kits and methods for their use in detecting expression ratios of genetic markers |
US15/798,922 US10689711B2 (en) | 2006-02-10 | 2017-10-31 | Test kits and methods for their use to detect genetic markers for urothelial carcinoma of the bladder and treatment thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/920,552 Continuation US9809860B2 (en) | 2006-02-10 | 2015-10-22 | Test kits and methods for their use in detecting expression ratios of genetic markers |
Publications (3)
Publication Number | Publication Date |
---|---|
US20180094323A1 US20180094323A1 (en) | 2018-04-05 |
US20200115757A9 true US20200115757A9 (en) | 2020-04-16 |
US10689711B2 US10689711B2 (en) | 2020-06-23 |
Family
ID=38345418
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/221,626 Abandoned US20090098553A1 (en) | 2006-02-10 | 2008-08-05 | Urine gene expression ratios for detection of cancer |
US12/843,435 Active 2028-03-07 US9702009B2 (en) | 2006-02-10 | 2010-07-26 | Urine gene expression ratios for detection of cancer |
US14/920,552 Active 2028-10-31 US9809860B2 (en) | 2006-02-10 | 2015-10-22 | Test kits and methods for their use in detecting expression ratios of genetic markers |
US15/798,922 Active 2027-09-28 US10689711B2 (en) | 2006-02-10 | 2017-10-31 | Test kits and methods for their use to detect genetic markers for urothelial carcinoma of the bladder and treatment thereof |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/221,626 Abandoned US20090098553A1 (en) | 2006-02-10 | 2008-08-05 | Urine gene expression ratios for detection of cancer |
US12/843,435 Active 2028-03-07 US9702009B2 (en) | 2006-02-10 | 2010-07-26 | Urine gene expression ratios for detection of cancer |
US14/920,552 Active 2028-10-31 US9809860B2 (en) | 2006-02-10 | 2015-10-22 | Test kits and methods for their use in detecting expression ratios of genetic markers |
Country Status (14)
Country | Link |
---|---|
US (4) | US20090098553A1 (en) |
EP (1) | EP1991699B1 (en) |
JP (2) | JP5964006B2 (en) |
KR (1) | KR101566368B1 (en) |
CN (1) | CN101410532B (en) |
AU (1) | AU2007212834B2 (en) |
BR (1) | BRPI0707642A2 (en) |
CA (1) | CA2642535C (en) |
ES (1) | ES2524333T3 (en) |
HK (1) | HK1129707A1 (en) |
IL (1) | IL193138A0 (en) |
MX (1) | MX2008009990A (en) |
NZ (1) | NZ545243A (en) |
WO (1) | WO2007091904A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114250299A (en) | 2004-07-23 | 2022-03-29 | 太平洋边缘有限公司 | Urine markers for detection of bladder cancer |
NZ545243A (en) * | 2006-02-10 | 2009-07-31 | Pacific Edge Biotechnology Ltd | Urine gene expression ratios for detection of cancer |
IL282783B2 (en) | 2006-05-18 | 2023-09-01 | Caris Mpi Inc | System and method for determining individualized medical intervention for a disease state |
US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
WO2010056337A2 (en) | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
JP5808349B2 (en) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | Biomarkers for theranosis |
BR112012025593A2 (en) | 2010-04-06 | 2019-06-25 | Caris Life Sciences Luxembourg Holdings | circulating biomarkers for disease |
CN102372773B (en) | 2010-08-11 | 2013-06-05 | 中国科学院生物物理研究所 | Human bladder cancer tumor marker, antibody thereof and application thereof |
NZ589251A (en) | 2010-11-12 | 2014-07-25 | Pacific Edge Ltd | Novel marker for detection of bladder cancer |
WO2016143805A1 (en) * | 2015-03-10 | 2016-09-15 | テオリアサイエンス株式会社 | Method for detecting bladder cancer |
EP3414340B1 (en) * | 2016-02-12 | 2023-08-09 | CureVac SE | Method for analyzing rna |
ES2921701T3 (en) | 2016-08-05 | 2022-08-30 | Univ New York State Res Found | Keratin 17 as a biomarker for bladder cancer |
JP6885581B2 (en) * | 2017-02-06 | 2021-06-16 | 学校法人東京歯科大学 | How to estimate the cutoff value in gastrin measurement |
US20220107320A1 (en) * | 2019-02-15 | 2022-04-07 | Incelldx, Inc. | Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein |
US20210232967A1 (en) * | 2020-01-28 | 2021-07-29 | GE Precision Healthcare LLC | Methods and systems for tuning a static model |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2100083A1 (en) | 1991-01-08 | 1992-07-09 | Michael C. Kiefer | Insulin-like growth factor binding protein |
US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
WO1998013493A2 (en) * | 1996-09-24 | 1998-04-02 | Lxr Biotechnology, Inc. | A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
US6495532B1 (en) * | 1997-03-19 | 2002-12-17 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
US6251638B1 (en) * | 1997-05-30 | 2001-06-26 | Diagen Corporation | Methods for detection of nucleic acid sequences in urine |
US6492144B1 (en) * | 1997-05-30 | 2002-12-10 | Diagen Corporation | Methods for detection of nucleic acid sequences in urine |
WO2000052204A2 (en) * | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
AU2001253140A1 (en) * | 2000-04-03 | 2001-10-15 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Tumor markers in ovarian cancer |
CA2320549A1 (en) * | 2000-09-25 | 2002-03-25 | Eastern Virginia Medical College | Biomarkers of transitional cell carcinoma of the bladder |
WO2002086084A2 (en) | 2001-04-04 | 2002-10-31 | Quark Biotech, Inc. | Sequence characteristics of bladder cancer |
US7514209B2 (en) * | 2001-06-18 | 2009-04-07 | Rosetta Inpharmatics Llc | Diagnosis and prognosis of breast cancer patients |
EP1285970A3 (en) * | 2001-06-26 | 2004-05-19 | National Taiwan University | Metastasis-associated genes |
US20040076955A1 (en) * | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
US20040018973A1 (en) * | 2002-01-25 | 2004-01-29 | University Of Pittsburgh | Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof |
US20050032065A1 (en) * | 2002-06-24 | 2005-02-10 | Afar Daniel E. H. | Methods of prognosis of prostate cancer |
AU2003298786A1 (en) | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | Compositions and methods for treating and diagnosing cancer |
US20050014165A1 (en) * | 2003-07-18 | 2005-01-20 | California Pacific Medical Center | Biomarker panel for colorectal cancer |
US9856533B2 (en) * | 2003-09-19 | 2018-01-02 | Biotheranostics, Inc. | Predicting breast cancer treatment outcome |
JP4912894B2 (en) * | 2004-02-19 | 2012-04-11 | イェール ユニバーシティー | Identification of oncoprotein biomarkers using proteomic technology |
CN114250299A (en) * | 2004-07-23 | 2022-03-29 | 太平洋边缘有限公司 | Urine markers for detection of bladder cancer |
NZ545243A (en) * | 2006-02-10 | 2009-07-31 | Pacific Edge Biotechnology Ltd | Urine gene expression ratios for detection of cancer |
WO2009133915A1 (en) * | 2008-04-30 | 2009-11-05 | 日本電気株式会社 | Cancer marker, method for evaluation of cancer by using the cancer marker, and evaluation reagent |
WO2009156858A1 (en) * | 2008-06-27 | 2009-12-30 | Institut Pasteur | Molecular signature of liver tumor grade and use to evaluate prognosis and therapeutic regimen |
-
2006
- 2006-02-10 NZ NZ545243A patent/NZ545243A/en unknown
-
2007
- 2007-02-09 MX MX2008009990A patent/MX2008009990A/en active IP Right Grant
- 2007-02-09 BR BRPI0707642-8A patent/BRPI0707642A2/en not_active Application Discontinuation
- 2007-02-09 CA CA2642535A patent/CA2642535C/en active Active
- 2007-02-09 CN CN200780010494.XA patent/CN101410532B/en active Active
- 2007-02-09 KR KR1020087022076A patent/KR101566368B1/en active IP Right Grant
- 2007-02-09 AU AU2007212834A patent/AU2007212834B2/en active Active
- 2007-02-09 ES ES07715981.2T patent/ES2524333T3/en active Active
- 2007-02-09 WO PCT/NZ2007/000029 patent/WO2007091904A1/en active Application Filing
- 2007-02-09 JP JP2008554172A patent/JP5964006B2/en active Active
- 2007-02-09 EP EP07715981.2A patent/EP1991699B1/en active Active
-
2008
- 2008-07-30 IL IL193138A patent/IL193138A0/en unknown
- 2008-08-05 US US12/221,626 patent/US20090098553A1/en not_active Abandoned
-
2009
- 2009-08-24 HK HK09107756.0A patent/HK1129707A1/en unknown
-
2010
- 2010-07-26 US US12/843,435 patent/US9702009B2/en active Active
-
2014
- 2014-07-25 JP JP2014151713A patent/JP6062399B2/en active Active
-
2015
- 2015-10-22 US US14/920,552 patent/US9809860B2/en active Active
-
2017
- 2017-10-31 US US15/798,922 patent/US10689711B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
NZ545243A (en) | 2009-07-31 |
EP1991699B1 (en) | 2014-08-20 |
US20090098553A1 (en) | 2009-04-16 |
AU2007212834A1 (en) | 2007-08-16 |
US9809860B2 (en) | 2017-11-07 |
EP1991699A4 (en) | 2009-08-26 |
US20160102368A1 (en) | 2016-04-14 |
CN101410532A (en) | 2009-04-15 |
HK1129707A1 (en) | 2009-12-04 |
US10689711B2 (en) | 2020-06-23 |
JP5964006B2 (en) | 2016-08-03 |
IL193138A0 (en) | 2009-02-11 |
KR101566368B1 (en) | 2015-11-13 |
KR20080098055A (en) | 2008-11-06 |
CA2642535A1 (en) | 2007-08-16 |
ES2524333T3 (en) | 2014-12-05 |
CN101410532B (en) | 2016-01-06 |
BRPI0707642A2 (en) | 2011-05-10 |
US20110151464A1 (en) | 2011-06-23 |
JP2014221073A (en) | 2014-11-27 |
JP2009528817A (en) | 2009-08-13 |
JP6062399B2 (en) | 2017-01-18 |
US9702009B2 (en) | 2017-07-11 |
EP1991699A1 (en) | 2008-11-19 |
US20180094323A1 (en) | 2018-04-05 |
AU2007212834B2 (en) | 2014-01-16 |
WO2007091904A1 (en) | 2007-08-16 |
CA2642535C (en) | 2019-06-18 |
MX2008009990A (en) | 2009-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10689711B2 (en) | Test kits and methods for their use to detect genetic markers for urothelial carcinoma of the bladder and treatment thereof | |
US10024859B2 (en) | Markers for detection of gastric cancer | |
US11208698B2 (en) | Methods for detection of markers bladder cancer and inflammatory conditions of the bladder and treatment thereof | |
NZ577012A (en) | Human zymogen granule protein 16 as a marker for detection of gastric cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: PACIFIC EDGE BIOTECHNOLOGY LIMITED, NEW ZEALAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GUILFORD, PARRY JOHN;PACIFIC EDGE BIOTECHNOLOGY LIMITED;SIGNING DATES FROM 20070209 TO 20100423;REEL/FRAME:044485/0613 Owner name: PACIFIC EDGE LIMITED, NEW ZEALAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GUILFORD, PARRY JOHN;PACIFIC EDGE BIOTECHNOLOGY LIMITED;SIGNING DATES FROM 20070209 TO 20100423;REEL/FRAME:044485/0613 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PTGR); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |